Oklahoma 2022 Regular Session

Oklahoma Senate Bill SB1338 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
3		-	SB1338 HFLR Page 1
4		-	BOLD FACE denotes Committee Amendments. 1
5		-	2
6		-	3
7		-	4
8		-	5
9		-	6
10		-	7
11		-	8
12		-	9
13		-	10
14		-	11
15		-	12
16		-	13
17		-	14
18		-	15
19		-	16
20		-	17
21		-	18
22		-	19
23		-	20
24		-	21
25		-	22
26		-	23
27		-	24
28		-
29		-	HOUSE OF REPRESENTATIVES - FLOOR VERSION
30		-
31		-	STATE OF OKLAHOMA
32		-
33		-	2nd Session of the 58th Legislature (2022)
	3	+	ENGR. S. B. NO. 1338 Page 1 1
	4	+	2
	5	+	3
	6	+	4
	7	+	5
	8	+	6
	9	+	7
	10	+	8
	11	+	9
	12	+	10
	13	+	11
	14	+	12
	15	+	13
	16	+	14
	17	+	15
	18	+	16
	19	+	17
	20	+	18
	21	+	19
	22	+	20
	23	+	21
	24	+	22
	25	+	23
	26	+	24
34	27
35	28		ENGROSSED SENATE
36	29		BILL NO. 1338 By: Bullard of the Senate
37	30
38	31		and
39	32
40	33		Dempsey of the House
41	34
42	35
43	36
44	37
45	38		[ controlled dangerous substances - certain substance
46	39		- exceptions - applicability of certain inclusion -
47	40		definitions used in the Oklahoma M edical Marijuana
48	41		and Patient Protection Act - effective date ]
49	42
50	43
51	44
52	45
53	46		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
54	47		SECTION 1. AMENDATORY 63 O.S. 2021 , Section 2-101, as
55	48		last amended by Section 1, Chapter 222, O.S.L. 2021, is amend ed to
56	49		read as follows:
57	50		Section 2-101. As used in the Uniform Controlled Dangerous
58	51		Substances Act:
59	52		1. “Administer” means the direct applicatio n of a controlled
60	53		dangerous substance, whether by injection, inhalation, ingestion or
61	54		any other means, to the bod y of a patient, animal or research
62	55		subject by:
63		-
64		-	SB1338 HFLR Page 2
65		-	BOLD FACE denotes Committee Amendments. 1
66		-	2
67		-	3
68		-	4
69		-	5
70		-	6
71		-	7
72		-	8
73		-	9
74		-	10
75		-	11
76		-	12
77		-	13
78		-	14
79		-	15
80		-	16
81		-	17
82		-	18
83		-	19
84		-	20
85		-	21
86		-	22
87		-	23
88		-	24
89		-
90	56		a. a practitioner (or, in the presence of the
91	57		practitioner, by the authorized agent of the
92	58		practitioner), or
93	59		b. the patient or research subject at the direction and
94	60		in the presence of the practitioner;
	61	+
	62	+	ENGR. S. B. NO. 1338 Page 2 1
	63	+	2
	64	+	3
	65	+	4
	66	+	5
	67	+	6
	68	+	7
	69	+	8
	70	+	9
	71	+	10
	72	+	11
	73	+	12
	74	+	13
	75	+	14
	76	+	15
	77	+	16
	78	+	17
	79	+	18
	80	+	19
	81	+	20
	82	+	21
	83	+	22
	84	+	23
	85	+	24
	86	+
95	87		2. “Agent” means a peace officer appointed by and who acts on
96	88		behalf of the Director of the Oklahoma State Bureau of Narcotics and
97	89		Dangerous Drugs Control or an authorized person wh o acts on behalf
98	90		of or at the direction of a person who manufactures, distributes ,
99	91		dispenses, prescribes, administers or uses for scientific purposes
100	92		controlled dangerous substances but does not include a common or
101	93		contract carrier, public warehouser or em ployee thereof, or a person
102	94		required to register under the Uniform Controlled Dan gerous
103	95		Substances Act;
104	96		3. “Board” means the Advisory Board to the Director of the
105	97		Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
106	98		4. “Bureau” means the Oklahoma State Bureau of Narcotics and
107	99		Dangerous Drugs Control;
108	100		5. “Coca leaves” includes cocaine and any compound,
109	101		manufacture, salt, derivative, mixture or preparation of coca
110	102		leaves, except derivatives of coca leaves whi ch do not contain
111	103		cocaine or ecgonine;
112	104		6. “Commissioner” or “Director” means the Director of the
113	105		Oklahoma State Burea u of Narcotics and Dangerous Drugs Control;
114		-
115		-	SB1338 HFLR Page 3
116		-	BOLD FACE denotes Committee Amendments. 1
117		-	2
118		-	3
119		-	4
120		-	5
121		-	6
122		-	7
123		-	8
124		-	9
125		-	10
126		-	11
127		-	12
128		-	13
129		-	14
130		-	15
131		-	16
132		-	17
133		-	18
134		-	19
135		-	20
136		-	21
137		-	22
138		-	23
139		-	24
140		-
141	106		7. “Control” means to add, remove or change the placement of a
142	107		drug, substance or immediate p recursor under the Uniform Controlled
143	108		Dangerous Substances Act;
144	109		8. “Controlled dangerous substance ” means a drug, substance or
145	110		immediate precursor in Schedules I through V of the Uniform
	111	+
	112	+	ENGR. S. B. NO. 1338 Page 3 1
	113	+	2
	114	+	3
	115	+	4
	116	+	5
	117	+	6
	118	+	7
	119	+	8
	120	+	9
	121	+	10
	122	+	11
	123	+	12
	124	+	13
	125	+	14
	126	+	15
	127	+	16
	128	+	17
	129	+	18
	130	+	19
	131	+	20
	132	+	21
	133	+	22
	134	+	23
	135	+	24
	136	+
146	137		Controlled Dangerous Substances Act or any drug, substance or
147	138		immediate precursor listed either temporari ly or permanently as a
148	139		federally controlled substance. Any conflict between stat e and
149	140		federal law with regard to the particular schedule in which a
150	141		substance is listed shall be resolved in favor of state law;
151	142		9. “Counterfeit substance” means a controlled substance which,
152	143		or the container or labeling of which without authorization, be ars
153	144		the trademark, trade name or other identifying marks, imprint,
154	145		number or device or any likeness thereof of a manufacturer,
155	146		distributor or dispenser other than the person w ho in fact
156	147		manufactured, distributed or dispensed the substance;
157	148		10. “Deliver” or “delivery” means the actual, constructive or
158	149		attempted transfer from one person to another of a controlled
159	150		dangerous substance or drug p araphernalia, whether or not there is
160	151		an agency relationship;
161	152		11. “Dispense” means to deliver a controlled dangerous
162	153		substance to an ultimate user or human research subject by or
163	154		pursuant to the lawful order of a practitioner , including the
164	155		prescribing, administering, packaging, labeling or compounding
165		-
166		-	SB1338 HFLR Page 4
167		-	BOLD FACE denotes Committee Amendments. 1
168		-	2
169		-	3
170		-	4
171		-	5
172		-	6
173		-	7
174		-	8
175		-	9
176		-	10
177		-	11
178		-	12
179		-	13
180		-	14
181		-	15
182		-	16
183		-	17
184		-	18
185		-	19
186		-	20
187		-	21
188		-	22
189		-	23
190		-	24
191		-
192	156		necessary to prepare the substance for such distribution.
193	157		“Dispenser” is a practitioner who delivers a controlled dangerous
194	158		substance to an ultimate user or human research subject;
195	159		12. “Distribute” means to deliver other than by administering
196	160		or dispensing a controlled dangerous substance;
	161	+
	162	+	ENGR. S. B. NO. 1338 Page 4 1
	163	+	2
	164	+	3
	165	+	4
	166	+	5
	167	+	6
	168	+	7
	169	+	8
	170	+	9
	171	+	10
	172	+	11
	173	+	12
	174	+	13
	175	+	14
	176	+	15
	177	+	16
	178	+	17
	179	+	18
	180	+	19
	181	+	20
	182	+	21
	183	+	22
	184	+	23
	185	+	24
	186	+
197	187		13. “Distributor” means a commercial entity engaged in the
198	188		distribution or reverse distribution of narcotics and dangerous
199	189		drugs and who complies with all regulations pr omulgated by the
200	190		federal Drug Enforce ment Administration and the Oklahoma State
201	191		Bureau of Narcotics and Dangerous Drug s Control;
202	192		14. “Drug” means articles:
203	193		a. recognized in the official United States Pharmacopeia,
204	194		official Homeopathic Pharmacopoeia of the United
205	195		States, or official National Formulary, or any
206	196		supplement to any of them,
207	197		b. intended for use in the diagnosis , cure, mitigation,
208	198		treatment or prevention of disease in man or other
209	199		animals,
210	200		c. other than food, intended to affect the structure or
211	201		any function of the body of man or othe r animals, and
212	202		d. intended for use as a component of any article
213	203		specified in this paragraph;
214	204		provided, however, the term “drug” does not include devices or their
215	205		components, parts or accessories;
216		-
217		-	SB1338 HFLR Page 5
218		-	BOLD FACE denotes Committee Amendments. 1
219		-	2
220		-	3
221		-	4
222		-	5
223		-	6
224		-	7
225		-	8
226		-	9
227		-	10
228		-	11
229		-	12
230		-	13
231		-	14
232		-	15
233		-	16
234		-	17
235		-	18
236		-	19
237		-	20
238		-	21
239		-	22
240		-	23
241		-	24
242		-
243	206		15. “Drug-dependent person” means a person who is using a
244	207		controlled dangerous substance and who is in a state of psychic or
245	208		physical dependence, or both, arising from administration of that
246	209		controlled dangerous substance on a continuous basis. Drug
247	210		dependence is characterize d by behavioral and other responses w hich
	211	+
	212	+	ENGR. S. B. NO. 1338 Page 5 1
	213	+	2
	214	+	3
	215	+	4
	216	+	5
	217	+	6
	218	+	7
	219	+	8
	220	+	9
	221	+	10
	222	+	11
	223	+	12
	224	+	13
	225	+	14
	226	+	15
	227	+	16
	228	+	17
	229	+	18
	230	+	19
	231	+	20
	232	+	21
	233	+	22
	234	+	23
	235	+	24
	236	+
248	237		include a strong compulsion to take the substance on a continuous
249	238		basis in order to experience its psychic effects, or to avoid the
250	239		discomfort of its absence;
251	240		16. “Home care agency” means any sole proprietorship,
252	241		partnership, association, corporation , or other organization which
253	242		administers, offers, or provides home care services , for a fee or
254	243		pursuant to a contract for such services, to clients in their place
255	244		of residence;
256	245		17. “Home care services” means skilled or personal care
257	246		services provided to clients in their place of residence for a fee;
258	247		18. “Hospice” means a centrally administered, nonprofit or for-
259	248		profit, medically directed, nurse -coordinated program which provides
260	249		a continuum of home and inpatient care for the terminally ill
261	250		patient and the patient’s family. Such term shall also include a
262	251		centrally administered, nonpr ofit or for-profit, medically directed,
263	252		nurse-coordinated program if such program is licensed pursuant to
264	253		the provisions of the Uniform Co ntrolled Dangerous Substances Act.
265	254		A hospice program offers palliative and supportive care to meet the
266	255		special needs arising out of the physical, emotional and spiritual
267		-
268		-	SB1338 HFLR Page 6
269		-	BOLD FACE denotes Committee Amendments. 1
270		-	2
271		-	3
272		-	4
273		-	5
274		-	6
275		-	7
276		-	8
277		-	9
278		-	10
279		-	11
280		-	12
281		-	13
282		-	14
283		-	15
284		-	16
285		-	17
286		-	18
287		-	19
288		-	20
289		-	21
290		-	22
291		-	23
292		-	24
293		-
294	256		stresses which are experienced during the final stages of illness
295	257		and during dying and bereavement. This care is availabl e twenty-
296	258		four (24) hours a day, seven (7) days a week, and is provided on the
297	259		basis of need, regardless of ability to pay. “Class A” Hospice
	260	+
	261	+	ENGR. S. B. NO. 1338 Page 6 1
	262	+	2
	263	+	3
	264	+	4
	265	+	5
	266	+	6
	267	+	7
	268	+	8
	269	+	9
	270	+	10
	271	+	11
	272	+	12
	273	+	13
	274	+	14
	275	+	15
	276	+	16
	277	+	17
	278	+	18
	279	+	19
	280	+	20
	281	+	21
	282	+	22
	283	+	23
	284	+	24
	285	+
298	286		refers to Medicare-certified hospices. “Class B” refers to all
299	287		other providers of hospice services;
300	288		19. “Imitation controlled substance ” means a substance that is
301	289		not a controlled dangerous sub stance, which by dosage unit
302	290		appearance, color, shape, size, markings or by representations made,
303	291		would lead a reasonable person to believ e that the substance is a
304	292		controlled dangerous substance. In the event the appearance of the
305	293		dosage unit is not reaso nably sufficient to establish that the
306	294		substance is an “imitation controlled substance ”, the court or
307	295		authority concerned should consider, in addition to all other
308	296		factors, the following factors as related to “representations made ”
309	297		in determining whether t he substance is an “imitation controlled
310	298		substance”:
311	299		a. statements made by an owner or by any other person in
312	300		control of the substance concerning the nature of the
313	301		substance, or its use or effect,
314	302		b. statements made to the recipient that the substance
315	303		may be resold for inordinate profit,
316	304		c. whether the substance is packaged in a manner normally
317	305		used for illicit controlled substa nces,
318		-
319		-	SB1338 HFLR Page 7
320		-	BOLD FACE denotes Committee Amendments. 1
321		-	2
322		-	3
323		-	4
324		-	5
325		-	6
326		-	7
327		-	8
328		-	9
329		-	10
330		-	11
331		-	12
332		-	13
333		-	14
334		-	15
335		-	16
336		-	17
337		-	18
338		-	19
339		-	20
340		-	21
341		-	22
342		-	23
343		-	24
344		-
345	306		d. evasive tactics or actions utilized by th e owner or
346	307		person in control of the substance to avoid detection
347	308		by law enforcement authorities,
	309	+
	310	+	ENGR. S. B. NO. 1338 Page 7 1
	311	+	2
	312	+	3
	313	+	4
	314	+	5
	315	+	6
	316	+	7
	317	+	8
	318	+	9
	319	+	10
	320	+	11
	321	+	12
	322	+	13
	323	+	14
	324	+	15
	325	+	16
	326	+	17
	327	+	18
	328	+	19
	329	+	20
	330	+	21
	331	+	22
	332	+	23
	333	+	24
	334	+
348	335		e. prior convictions, if any, of an owner, or any other
349	336		person in control of the object, under state or
350	337		federal law related to controlled substances or fraud,
351	338		and
352	339		f. the proximity of the substances to controlled
353	340		dangerous substances;
354	341		20. “Immediate precursor” means a substance which the Director
355	342		has found to be and by regulation designates as being the principal
356	343		compound commonly used or produced primarily for use, and which is
357	344		an immediate chemical intermediary used, or likely to be used, in
358	345		the manufacture of a controlled dangerous substance, the control of
359	346		which is necessary to prevent, curtail or limit such m anufacture;
360	347		21. “Laboratory” means a laboratory a pproved by the Director as
361	348		proper to be entrusted with the custody of controlled dangerous
362	349		substances and the use of controlled dangerous substances for
363	350		scientific and medical purposes and for purposes of i nstruction;
364	351		22. “Manufacture” means the production, preparation,
365	352		propagation, compounding or processing of a controlled dangerous
366	353		substance, either directly or indirectly by extraction from
367	354		substances of natural or synthetic origin, or independently by me ans
368	355		of chemical synthesis or by a combination of e xtraction and chemical
369		-
370		-	SB1338 HFLR Page 8
371		-	BOLD FACE denotes Committee Amendments. 1
372		-	2
373		-	3
374		-	4
375		-	5
376		-	6
377		-	7
378		-	8
379		-	9
380		-	10
381		-	11
382		-	12
383		-	13
384		-	14
385		-	15
386		-	16
387		-	17
388		-	18
389		-	19
390		-	20
391		-	21
392		-	22
393		-	23
394		-	24
395		-
396	356		synthesis. “Manufacturer” includes any person who package s,
397	357		repackages or labels any container of any controlled dangerous
	358	+
	359	+	ENGR. S. B. NO. 1338 Page 8 1
	360	+	2
	361	+	3
	362	+	4
	363	+	5
	364	+	6
	365	+	7
	366	+	8
	367	+	9
	368	+	10
	369	+	11
	370	+	12
	371	+	13
	372	+	14
	373	+	15
	374	+	16
	375	+	17
	376	+	18
	377	+	19
	378	+	20
	379	+	21
	380	+	22
	381	+	23
	382	+	24
	383	+
398	384		substance, except practitioners who dispense or compound
399	385		prescription orders for delivery to the ultimate con sumer;
400	386		23. “Marijuana” means all parts of the plant Cannabis sativa
401	387		L., whether growing or not; the seeds thereof; the resin extracted
402	388		from any part of such plant; and every compound, manufacture, salt,
403	389		derivative, mixture or preparation of such plant, it s seeds or
404	390		resin, but shall not include:
405	391		a. the mature stalks of such plant or fi ber produced from
406	392		such stalks,
407	393		b. oil or cake made from the seeds of such plant ,
408	394		including cannabidiol derived from the seeds of the
409	395		marijuana plant,
410	396		c. any other compound, ma nufacture, salt, derivative,
411	397		mixture or preparation of such mature stalks (except
412	398		the resin extracted therefrom), including cannabidiol
413	399		derived from mature stalks, fiber, oil or cake,
414	400		d. the sterilized seed of such plant which is incapable
415	401		of germination,
416	402		e. for any person participating in a clinical trial to
417	403		administer cannabidiol for the treatment of severe
418	404		forms of epilepsy pursuant to Section 2 -802 of this
419	405		title, a drug or substance approved by the feder al
420		-
421		-	SB1338 HFLR Page 9
422		-	BOLD FACE denotes Committee Amendments. 1
423		-	2
424		-	3
425		-	4
426		-	5
427		-	6
428		-	7
429		-	8
430		-	9
431		-	10
432		-	11
433		-	12
434		-	13
435		-	14
436		-	15
437		-	16
438		-	17
439		-	18
440		-	19
441		-	20
442		-	21
443		-	22
444		-	23
445		-	24
446		-
447	406		Food and Drug Administration for use by those
448	407		participants,
	408	+
	409	+	ENGR. S. B. NO. 1338 Page 9 1
	410	+	2
	411	+	3
	412	+	4
	413	+	5
	414	+	6
	415	+	7
	416	+	8
	417	+	9
	418	+	10
	419	+	11
	420	+	12
	421	+	13
	422	+	14
	423	+	15
	424	+	16
	425	+	17
	426	+	18
	427	+	19
	428	+	20
	429	+	21
	430	+	22
	431	+	23
	432	+	24
	433	+
449	434		f. for any person or the parents, legal guardians or
450	435		caretakers of the person who have received a written
451	436		certification from a physician licensed in this state
452	437		that the person has been diagnose d by a physician as
453	438		having Lennox-Gastaut syndrome, Dravet syndrome, also
454	439		known as severe myoclonic epilepsy of infancy, or any
455	440		other severe form of epilepsy that is not adequately
456	441		treated by traditional medical therapies, spasticity
457	442		due to multiple sclero sis or due to paraplegia,
458	443		intractable nausea and v omiting, appetite stimulation
459	444		with chronic wasting diseases, the substance
460	445		cannabidiol, a nonpsychoactive cannabinoid, found in
461	446		the plant Cannabis sativa L. or any other preparation
462	447		thereof, that has a tetr ahydrocannabinol concentration
463	448		of not more than three-tenths of one percent (0.3%)
464	449		and that is delivered to the patient in the form of a
465	450		liquid,
466	451		g. any federal Food-and-Drug-Administration-approved drug
467	452		or substance, or
468	453		h. industrial hemp, from the plant C annabis sativa L. and
469	454		any part of such plant, whet her growing or not, with a
470	455		delta-9 tetrahydrocannabinol concentration of not more
471		-
472		-	SB1338 HFLR Page 10
473		-	BOLD FACE denotes Committee Amendments. 1
474		-	2
475		-	3
476		-	4
477		-	5
478		-	6
479		-	7
480		-	8
481		-	9
482		-	10
483		-	11
484		-	12
485		-	13
486		-	14
487		-	15
488		-	16
489		-	17
490		-	18
491		-	19
492		-	20
493		-	21
494		-	22
495		-	23
496		-	24
497		-
498	456		than three-tenths of one percent (0.3%) on a dry
499	457		weight basis which shall only be grown pursuant to the
	458	+
	459	+	ENGR. S. B. NO. 1338 Page 10 1
	460	+	2
	461	+	3
	462	+	4
	463	+	5
	464	+	6
	465	+	7
	466	+	8
	467	+	9
	468	+	10
	469	+	11
	470	+	12
	471	+	13
	472	+	14
	473	+	15
	474	+	16
	475	+	17
	476	+	18
	477	+	19
	478	+	20
	479	+	21
	480	+	22
	481	+	23
	482	+	24
	483	+
500	484		Oklahoma Industrial Hemp Program and may be shipped
501	485		intrastate and interstate;
502	486		24. “Medical purpose” means an intention to utilize a
503	487		controlled dangerous substance for physical or mental treatment, for
504	488		diagnosis, or for the prevention of a disease condition not in
505	489		violation of any state or federal law and not for the purpos e of
506	490		satisfying physiological or psychological dependence or other abuse;
507	491		25. “Mid-level practitioner” means an Advanced Practice
508	492		Registered Nurse as defined and within parameters specified in
509	493		Section 567.3a of Title 59 of the Oklahoma Statutes, or a cert ified
510	494		animal euthanasia technician as defined in Section 698.2 of Title 59
511	495		of the Oklahoma Statutes, or an animal control officer registered by
512	496		the Oklahoma State Bureau of Narcotics and Dangerous Drugs Con trol
513	497		under subsection B of Section 2 -301 of this title within the
514	498		parameters of such officer ’s duties under Sections 501 through 50 8
515	499		of Title 4 of the Oklahoma Statutes;
516	500		26. “Narcotic drug” means any of the following, whether
517	501		produced directly or indirect ly by extraction from substances of
518	502		vegetable origin, or independently by means of chemical synthesis,
519	503		or by a combination of extra ction and chemical synthesis:
520	504		a. opium, coca leaves and opiates,
521		-
522		-	SB1338 HFLR Page 11
523		-	BOLD FACE denotes Committee Amendments. 1
524		-	2
525		-	3
526		-	4
527		-	5
528		-	6
529		-	7
530		-	8
531		-	9
532		-	10
533		-	11
534		-	12
535		-	13
536		-	14
537		-	15
538		-	16
539		-	17
540		-	18
541		-	19
542		-	20
543		-	21
544		-	22
545		-	23
546		-	24
547		-
548	505		b. a compound, manufacture, salt, derivative or
549	506		preparation of opium, coca leaves or opiates,
	507	+
	508	+	ENGR. S. B. NO. 1338 Page 11 1
	509	+	2
	510	+	3
	511	+	4
	512	+	5
	513	+	6
	514	+	7
	515	+	8
	516	+	9
	517	+	10
	518	+	11
	519	+	12
	520	+	13
	521	+	14
	522	+	15
	523	+	16
	524	+	17
	525	+	18
	526	+	19
	527	+	20
	528	+	21
	529	+	22
	530	+	23
	531	+	24
	532	+
550	533		c. cocaine, its salts, optical and geometric isomers, and
551	534		salts of isomers,
552	535		d. ecgonine, its derivatives, their salts, isomers and
553	536		salts of isomers, and
554	537		e. a substance, and any compound, manufacture, salt,
555	538		derivative or preparation thereof, which is chemically
556	539		identical with any of the substances referred to in
557	540		subparagraphs a through d of this paragr aph, except
558	541		that the words “narcotic drug” as used in Section 2 -
559	542		101 et seq. of this title shall not include
560	543		decocainized coca leaves or extracts of coca leaves,
561	544		which extracts do not contain cocaine or ecgonine;
562	545		27. “Opiate” or “opioid” means any Schedule II, III, IV or V
563	546		substance having an addiction -forming or addiction -sustaining
564	547		liability similar to morphine or being capable of conversion into a
565	548		drug having such addiction -forming or addiction-sustaining
566	549		liability. The terms do not include, unless spec ifically designated
567	550		as controlled under the Uniform Controlled Dangerous Substances Act,
568	551		the dextrorotatory i somer of 3-methoxy-n-methyl-morphinan and its
569	552		salts (dextromethorp han). The terms do include the racemic and
570	553		levorotatory forms;
571		-
572		-	SB1338 HFLR Page 12
573		-	BOLD FACE denotes Committee Amendments. 1
574		-	2
575		-	3
576		-	4
577		-	5
578		-	6
579		-	7
580		-	8
581		-	9
582		-	10
583		-	11
584		-	12
585		-	13
586		-	14
587		-	15
588		-	16
589		-	17
590		-	18
591		-	19
592		-	20
593		-	21
594		-	22
595		-	23
596		-	24
597		-
598	554		28. “Opium poppy” means the plant of the species Papaver
599	555		somniferum L., except the seeds thereof;
	556	+
	557	+	ENGR. S. B. NO. 1338 Page 12 1
	558	+	2
	559	+	3
	560	+	4
	561	+	5
	562	+	6
	563	+	7
	564	+	8
	565	+	9
	566	+	10
	567	+	11
	568	+	12
	569	+	13
	570	+	14
	571	+	15
	572	+	16
	573	+	17
	574	+	18
	575	+	19
	576	+	20
	577	+	21
	578	+	22
	579	+	23
	580	+	24
	581	+
600	582		29. “Peace officer” means a police officer, sheriff, deputy
601	583		sheriff, district attorney ’s investigator, investigator from the
602	584		Office of the Attorney General, or any other per son elected or
603	585		appointed by law to enforce any of the criminal laws of this state
604	586		or of the United States;
605	587		30. “Person” means an individual, corporation, government or
606	588		governmental subdivision or agency, business trust, estate, trust,
607	589		partnership or assoc iation, or any other legal entity;
608	590		31. “Poppy straw” means all parts, except the seeds, of the
609	591		opium poppy, after mowing;
610	592		32. “Practitioner” means:
611	593		a. (1) a medical doctor or osteopathic physician,
612	594		(2) a dentist,
613	595		(3) a podiatrist,
614	596		(4) an optometrist,
615	597		(5) a veterinarian,
616	598		(6) a physician assistant or Advanced Practice
617	599		Registered Nurse under the supervision of a
618	600		licensed medical doctor or osteopathic physician,
619	601		(7) a scientific investigator, or
620	602		(8) any other person,
621		-
622		-	SB1338 HFLR Page 13
623		-	BOLD FACE denotes Committee Amendments. 1
624		-	2
625		-	3
626		-	4
627		-	5
628		-	6
629		-	7
630		-	8
631		-	9
632		-	10
633		-	11
634		-	12
635		-	13
636		-	14
637		-	15
638		-	16
639		-	17
640		-	18
641		-	19
642		-	20
643		-	21
644		-	22
645		-	23
646		-	24
647		-
648	603		licensed, registered or otherwise permitte d to
649	604		prescribe, distribute, dispense, conduct research with
650	605		respect to, use for scientific purposes or administer
	606	+
	607	+	ENGR. S. B. NO. 1338 Page 13 1
	608	+	2
	609	+	3
	610	+	4
	611	+	5
	612	+	6
	613	+	7
	614	+	8
	615	+	9
	616	+	10
	617	+	11
	618	+	12
	619	+	13
	620	+	14
	621	+	15
	622	+	16
	623	+	17
	624	+	18
	625	+	19
	626	+	20
	627	+	21
	628	+	22
	629	+	23
	630	+	24
	631	+
651	632		a controlled dangerous substance in the course of
652	633		professional practice or research in this state, or
653	634		b. a pharmacy, hospital, laboratory or o ther institution
654	635		licensed, registered or otherwise permitted to
655	636		distribute, dispense, conduct research with respect
656	637		to, use for scientific purposes or administer a
657	638		controlled dangerous substance in the course of
658	639		professional practice or research in this st ate;
659	640		33. “Production” includes the manufacture, planting,
660	641		cultivation, growing or harvesting of a cont rolled dangerous
661	642		substance;
662	643		34. “State” means the State of Oklahoma this state or any other
663	644		state of the United States;
664	645		35. “Ultimate user” means a person who lawfully possesses a
665	646		controlled dangerous substance for the person ’s own use or for the
666	647		use of a member of the person ’s household or for administration to
667	648		an animal owned by the person or by a member of the person ’s
668	649		household;
669	650		36. “Drug paraphernalia” means all equipment, products and
670	651		materials of any kind which are used, intended for use, or fashi oned
671	652		specifically for use in planting, propagating, cultivating, growing ,
672		-
673		-	SB1338 HFLR Page 14
674		-	BOLD FACE denotes Committee Amendments. 1
675		-	2
676		-	3
677		-	4
678		-	5
679		-	6
680		-	7
681		-	8
682		-	9
683		-	10
684		-	11
685		-	12
686		-	13
687		-	14
688		-	15
689		-	16
690		-	17
691		-	18
692		-	19
693		-	20
694		-	21
695		-	22
696		-	23
697		-	24
698		-
699	653		harvesting, manufacturing, compounding, converting, producing,
700	654		processing, preparing, testing, analyzing, packaging, repackaging,
701	655		storing, containing, concealing, injecting, ingestin g, inhaling or
	656	+
	657	+	ENGR. S. B. NO. 1338 Page 14 1
	658	+	2
	659	+	3
	660	+	4
	661	+	5
	662	+	6
	663	+	7
	664	+	8
	665	+	9
	666	+	10
	667	+	11
	668	+	12
	669	+	13
	670	+	14
	671	+	15
	672	+	16
	673	+	17
	674	+	18
	675	+	19
	676	+	20
	677	+	21
	678	+	22
	679	+	23
	680	+	24
	681	+
702	682		otherwise introducing into the human body, a controlled d angerous
703	683		substance in violation of the Uniform Controlled Dangerous
704	684		Substances Act including, but not limited to:
705	685		a. kits used, intended for use, or fashioned specifically
706	686		for use in planting, propagating, cultivating, growing
707	687		or harvesting of any species of plant which is a
708	688		controlled dangerous substance or from which a
709	689		controlled dangerous substance can be derived,
710	690		b. kits used, intended for use, or fashioned specifically
711	691		for use in manufacturing, compounding, converting,
712	692		producing, processing or preparin g controlled
713	693		dangerous substances,
714	694		c. isomerization devices used, intended for us e, or
715	695		fashioned specifically for use in increasing the
716	696		potency of any species of plant which is a contr olled
717	697		dangerous substance,
718	698		d. testing equipment used, intended for use, or fashioned
719	699		specifically for use in identifying, or in analyzing
720	700		the strength, effectiveness or purity of controlled
721	701		dangerous substances,
722		-
723		-	SB1338 HFLR Page 15
724		-	BOLD FACE denotes Committee Amendments. 1
725		-	2
726		-	3
727		-	4
728		-	5
729		-	6
730		-	7
731		-	8
732		-	9
733		-	10
734		-	11
735		-	12
736		-	13
737		-	14
738		-	15
739		-	16
740		-	17
741		-	18
742		-	19
743		-	20
744		-	21
745		-	22
746		-	23
747		-	24
748		-
749	702		e. scales and balances used, intended for us e, or
750	703		fashioned specifically for use in weighing or
751	704		measuring controlled dangerous substances,
	705	+
	706	+	ENGR. S. B. NO. 1338 Page 15 1
	707	+	2
	708	+	3
	709	+	4
	710	+	5
	711	+	6
	712	+	7
	713	+	8
	714	+	9
	715	+	10
	716	+	11
	717	+	12
	718	+	13
	719	+	14
	720	+	15
	721	+	16
	722	+	17
	723	+	18
	724	+	19
	725	+	20
	726	+	21
	727	+	22
	728	+	23
	729	+	24
	730	+
752	731		f. diluents and adulterants, such as quinine
753	732		hydrochloride, mannitol, mannite, dextrose and
754	733		lactose, used, intended for use, or fashioned
755	734		specifically for use in cutting controlled dangerous
756	735		substances,
757	736		g. separation gins and sifters used, intended for use, or
758	737		fashioned specifically for use in removing twigs and
759	738		seeds from, or in otherwise cleaning or refining,
760	739		marijuana,
761	740		h. blenders, bowls, containers, spoons and mixing devices
762	741		used, intended for use, or fashioned specifically for
763	742		use in compounding controlled dangerous substances,
764	743		i. capsules, balloons, envelope s and other containers
765	744		used, intended for use, or fashioned specifically for
766	745		use in packaging small qua ntities of controlled
767	746		dangerous substances,
768	747		j. containers and other obje cts used, intended for use,
769	748		or fashioned specifically for use in parenterally
770	749		injecting controlled dangerous substances into the
771	750		human body,
772		-
773		-	SB1338 HFLR Page 16
774		-	BOLD FACE denotes Committee Amendments. 1
775		-	2
776		-	3
777		-	4
778		-	5
779		-	6
780		-	7
781		-	8
782		-	9
783		-	10
784		-	11
785		-	12
786		-	13
787		-	14
788		-	15
789		-	16
790		-	17
791		-	18
792		-	19
793		-	20
794		-	21
795		-	22
796		-	23
797		-	24
798		-
799	751		k. hypodermic syringes, needles and other o bjects used,
800	752		intended for use, or fashioned specifically for use in
801	753		parenterally injecting controlled dangerous substances
802	754		into the human body,
	755	+
	756	+	ENGR. S. B. NO. 1338 Page 16 1
	757	+	2
	758	+	3
	759	+	4
	760	+	5
	761	+	6
	762	+	7
	763	+	8
	764	+	9
	765	+	10
	766	+	11
	767	+	12
	768	+	13
	769	+	14
	770	+	15
	771	+	16
	772	+	17
	773	+	18
	774	+	19
	775	+	20
	776	+	21
	777	+	22
	778	+	23
	779	+	24
	780	+
803	781		l. objects used, intended for use, or fashioned
804	782		specifically for use in ingesting, inhaling or
805	783		otherwise introducing marijuana, cocaine, hashish or
806	784		hashish oil into the human body, suc h as:
807	785		(1) metal, wooden, acrylic, glass, stone, plastic or
808	786		ceramic pipes with or without screens, permanent
809	787		screens, hashish heads or punctured metal bowls,
810	788		(2) water pipes,
811	789		(3) carburetion tubes and devices,
812	790		(4) smoking and carburetion masks,
813	791		(5) roach clips, meaning objects used to hold burning
814	792		material, such as a marijuana cigarette , that has
815	793		become too small or too short to be held in the
816	794		hand,
817	795		(6) miniature cocaine spoons and cocaine vials,
818	796		(7) chamber pipes,
819	797		(8) carburetor pipes,
820	798		(9) electric pipes,
821	799		(10) air-driven pipes,
822	800		(11) chillums,
823		-
824		-	SB1338 HFLR Page 17
825		-	BOLD FACE denotes Committee Amendments. 1
826		-	2
827		-	3
828		-	4
829		-	5
830		-	6
831		-	7
832		-	8
833		-	9
834		-	10
835		-	11
836		-	12
837		-	13
838		-	14
839		-	15
840		-	16
841		-	17
842		-	18
843		-	19
844		-	20
845		-	21
846		-	22
847		-	23
848		-	24
849		-
850	801		(12) bongs, or
851	802		(13) ice pipes or chillers,
852	803		m. all hidden or novelty pipes, and
	804	+
	805	+	ENGR. S. B. NO. 1338 Page 17 1
	806	+	2
	807	+	3
	808	+	4
	809	+	5
	810	+	6
	811	+	7
	812	+	8
	813	+	9
	814	+	10
	815	+	11
	816	+	12
	817	+	13
	818	+	14
	819	+	15
	820	+	16
	821	+	17
	822	+	18
	823	+	19
	824	+	20
	825	+	21
	826	+	22
	827	+	23
	828	+	24
	829	+
853	830		n. any pipe that has a tobacco bowl or chamber of less
854	831		than one-half (1/2) inch in diameter in which there is
855	832		any detectable residue of any controlled dangerous
856	833		substance as defined in this section or any other
857	834		substances not legal for possession or use;
858	835		provided, however, the term “drug paraphernalia” shall not include
859	836		separation gins intended for use in preparing tea or spice, clamps
860	837		used for constructing electrical equipment, water pipes designed for
861	838		ornamentation in which no detectable amount of an illegal substance
862	839		is found or pipes designed and used solely for s moking tobacco,
863	840		traditional pipes of an American Indian tribal religious cerem ony,
864	841		or antique pipes that are thirty (30) years of age or older;
865	842		37. a. “Synthetic controlled substance” means a substance:
866	843		(1) the chemical structure of which is substantially
867	844		similar to the chemical structure of a controlled
868	845		dangerous substance in Sched ule I or II,
869	846		(2) which has a stimulant, depressant, or
870	847		hallucinogenic effect on t he central nervous
871	848		system that is substantially similar to or
872	849		greater than the stim ulant, depressant or
873	850		hallucinogenic effect on the central nervous
874		-
875		-	SB1338 HFLR Page 18
876		-	BOLD FACE denotes Committee Amendments. 1
877		-	2
878		-	3
879		-	4
880		-	5
881		-	6
882		-	7
883		-	8
884		-	9
885		-	10
886		-	11
887		-	12
888		-	13
889		-	14
890		-	15
891		-	16
892		-	17
893		-	18
894		-	19
895		-	20
896		-	21
897		-	22
898		-	23
899		-	24
900		-
901	851		system of a controlled dan gerous substance in
902	852		Schedule I or II, or
	853	+
	854	+	ENGR. S. B. NO. 1338 Page 18 1
	855	+	2
	856	+	3
	857	+	4
	858	+	5
	859	+	6
	860	+	7
	861	+	8
	862	+	9
	863	+	10
	864	+	11
	865	+	12
	866	+	13
	867	+	14
	868	+	15
	869	+	16
	870	+	17
	871	+	18
	872	+	19
	873	+	20
	874	+	21
	875	+	22
	876	+	23
	877	+	24
	878	+
903	879		(3) with respect to a particular person, which such
904	880		person represents or intends to have a stimulant,
905	881		depressant, or halluc inogenic effect on the
906	882		central nervous system that is substantially
907	883		similar to or greater th an the stimulant,
908	884		depressant, or hallucinogenic effect on the
909	885		central nervous system of a controlled dangerous
910	886		substance in Schedule I or II.
911	887		b. The designation of gamma butyrolactone or any other
912	888		chemical as a precursor, pursuant to Section 2 -322 of
913	889		this title, does not preclude a finding pursuant to
914	890		subparagraph a of this paragraph t hat the chemical is
915	891		a synthetic controlled substance.
916	892		c. “Synthetic controlled subs tance” does not include:
917	893		(1) a controlled dangerous substance,
918	894		(2) any substance for which t here is an approved new
919	895		drug application,
920	896		(3) with respect to a particular person any
921	897		substance, if an exemption is in effect for
922	898		investigational use, for that pers on under the
923	899		provisions of Section 505 of the Federal Food,
924	900		Drug and Cosmetic Act, Title 21 of the United
925		-
926		-	SB1338 HFLR Page 19
927		-	BOLD FACE denotes Committee Amendments. 1
928		-	2
929		-	3
930		-	4
931		-	5
932		-	6
933		-	7
934		-	8
935		-	9
936		-	10
937		-	11
938		-	12
939		-	13
940		-	14
941		-	15
942		-	16
943		-	17
944		-	18
945		-	19
946		-	20
947		-	21
948		-	22
949		-	23
950		-	24
951		-
952	901		States Code, Section 355, to the extent conduct
	902	+
	903	+	ENGR. S. B. NO. 1338 Page 19 1
	904	+	2
	905	+	3
	906	+	4
	907	+	5
	908	+	6
	909	+	7
	910	+	8
	911	+	9
	912	+	10
	913	+	11
	914	+	12
	915	+	13
	916	+	14
	917	+	15
	918	+	16
	919	+	17
	920	+	18
	921	+	19
	922	+	20
	923	+	21
	924	+	22
	925	+	23
	926	+	24
	927	+
953	928		with respect to such substance is pursuant to
954	929		such exemption, or
955	930		(4) any substance to the extent not i ntended for
956	931		human consumption before such an exemption takes
957	932		effect with respect to that sub stance.
958	933		d. Prima facie evidence that a substance containing
959	934		salvia divinorum has been enhanced, concentrated or
960	935		chemically or physically altered shall give rise to a
961	936		rebuttable presumption that the substance is a
962	937		synthetic controlled substance;
963	938		38. “Tetrahydrocannabinols” means delta-9 tetrahydrocannabinol ,
964	939		the primary psychotropic ca nnabinoid in marijuana, and all isomers,
965	940		precursors, and other variations of tetrahydrocannabinol and all
966	941		substances that have been chemically synthesized to emulate the
967	942		tetrahydrocannabinols of marijuana including but not limited to
968	943		delta-8 or delta-10 tetrahydrocannabinol;
969	944		39. “Isomer” means the optical isomer, except as used in
970	945		subsections C and F of Section 2 -204 of this title and paragraph 4
971	946		of subsection A of Section 2 -206 of this title. As used in
972	947		subsections C and F of Section 2 -204 of this title, “isomer” means
973	948		the optical, positional or geometric isomer. As used in paragraph 4
974	949		of subsection A of Section 2 -206 of this title, the term “isomer”
975	950		means the optical or geo metric isomer;
976	951
977		-	SB1338 HFLR Page 20
978		-	BOLD FACE denotes Committee Amendments. 1
	952	+	ENGR. S. B. NO. 1338 Page 20 1
979	953		2
980	954		3
981	955		4
982	956		5
983	957		6
984	958		7
985	959		8
986	960		9
987	961		10
988	962		11
989	963		12
990	964		13
991	965		14
992	966		15
993	967		16
994	968		17
995	969		18
996	970		19
997	971		20
998	972		21
999	973		22
1000	974		23
1001	975		24
1002	976
1003	977		40. “Hazardous materials” means materials, whether solid,
1004	978		liquid or gas, which are toxic to human, animal, aquatic or plant
1005	979		life, and the disposal of which materials is controlled by state or
1006	980		federal guidelines;
1007	981		41. “Anhydrous ammonia” means any substance that exhibits
1008	982		cryogenic evaporative behavior and tests positive for ammonia;
1009	983		42. “Acute pain” means pain, whether resulting from disease,
1010	984		accidental or intentional trauma or other cause, that the
1011	985		practitioner reasonably expects to last on ly a short period of time.
1012	986		“Acute pain” does not include chronic pain, pain bein g treated as
1013	987		part of cancer care, hospice or other end -of-life care, or pain
1014	988		being treated as part of palliative care;
1015	989		43. “Chronic pain” means pain that persists beyond the usual
1016	990		course of an acute disease or healing of an injury. “Chronic pain”
1017	991		may or may not be associated with an acute or chronic pathologic
1018	992		process that causes continuous or intermittent pain over months or
1019	993		years;
1020	994		44. “Initial prescription ” means a prescription issued to a
1021	995		patient who:
1022	996		a. has never previously been issued a prescription for
1023	997		the drug or its pharmaceutical equivalent in the past
1024	998		year, or
1025	999		b. requires a prescription for the drug or its
1026	1000		pharmaceutical equivalent due to a surgical procedure
1027	1001
1028		-	SB1338 HFLR Page 21
1029		-	BOLD FACE denotes Committee Amendments. 1
	1002	+	ENGR. S. B. NO. 1338 Page 21 1
1030	1003		2
1031	1004		3
1032	1005		4
1033	1006		5
1034	1007		6
1035	1008		7
1036	1009		8
1037	1010		9
1038	1011		10
1039	1012		11
1040	1013		12
1041	1014		13
1042	1015		14
1043	1016		15
1044	1017		16
1045	1018		17
1046	1019		18
1047	1020		19
1048	1021		20
1049	1022		21
1050	1023		22
1051	1024		23
1052	1025		24
1053	1026
1054	1027		or new acute event and has previously had a
1055	1028		prescription for the drug or its pharmaceut ical
1056	1029		equivalent within the past year.
1057	1030		When determining whether a patient was previously issued a
1058	1031		prescription for a drug or its pharmaceutical equivalent, the
1059	1032		practitioner shall consult with the patient and review the medical
1060	1033		record and prescription monito ring information of the patient;
1061	1034		45. “Patient-provider agreement” means a written contract or
1062	1035		agreement that is executed between a practitioner and a patient,
1063	1036		prior to the commencement of treatment for chronic pain using an
1064	1037		opioid drug as a means to:
1065	1038		a. explain the possible risk of development of physical
1066	1039		or psychological dependence in the patient and prevent
1067	1040		the possible development of addiction,
1068	1041		b. document the understanding of both the practitioner
1069	1042		and the patient regarding the patient -provider
1070	1043		agreement of the patient,
1071	1044		c. establish the rights of the patient in association
1072	1045		with treatment and the obligations of the patient in
1073	1046		relation to the responsible use, discontinuation o f
1074	1047		use, and storage of opioid drugs , including any
1075	1048		restrictions on the refill of p rescriptions or the
1076	1049		acceptance of opioid prescriptions from practitioners,
1077	1050
1078		-	SB1338 HFLR Page 22
1079		-	BOLD FACE denotes Committee Amendments. 1
	1051	+	ENGR. S. B. NO. 1338 Page 22 1
1080	1052		2
1081	1053		3
1082	1054		4
1083	1055		5
1084	1056		6
1085	1057		7
1086	1058		8
1087	1059		9
1088	1060		10
1089	1061		11
1090	1062		12
1091	1063		13
1092	1064		14
1093	1065		15
1094	1066		16
1095	1067		17
1096	1068		18
1097	1069		19
1098	1070		20
1099	1071		21
1100	1072		22
1101	1073		23
1102	1074		24
1103	1075
1104	1076		d. identify the specific medications and other modes of
1105	1077		treatment, including physical therapy or exe rcise,
1106	1078		relaxation or psychological counseling, that are
1107	1079		included as a part of the patient-provider agreement,
1108	1080		e. specify the measures the practitioner may employ to
1109	1081		monitor the compliance of the patient including, but
1110	1082		not limited to, random specimen screen s and pill
1111	1083		counts, and
1112	1084		f. delineate the process for terminating the agreement ,
1113	1085		including the consequences if the practitioner has
1114	1086		reason to believe that the patient is not complying
1115	1087		with the terms of the agreement. Compliance with the
1116	1088		“consent items” shall constitute a valid, informed
1117	1089		consent for opioid therapy. The practitioner shal l be
1118	1090		held harmless from civil litigation for failure to
1119	1091		treat pain if the event occurs because of nonadherence
1120	1092		by the patient with any of the provisions of the
1121	1093		patient-provider agreement;
1122	1094		46. “Serious illness” means a medical illness or physical
1123	1095		injury or condition that substantially affects quality of life for
1124	1096		more than a short period of time. “Serious illness” includes, but
1125	1097		is not limited to, Alzheimer ’s disease or related dementias, lung
1126	1098		disease, cancer, heart failure, renal failure, liver failure or
1127	1099
1128		-	SB1338 HFLR Page 23
1129		-	BOLD FACE denotes Committee Amendments. 1
	1100	+	ENGR. S. B. NO. 1338 Page 23 1
1130	1101		2
1131	1102		3
1132	1103		4
1133	1104		5
1134	1105		6
1135	1106		7
1136	1107		8
1137	1108		9
1138	1109		10
1139	1110		11
1140	1111		12
1141	1112		13
1142	1113		14
1143	1114		15
1144	1115		16
1145	1116		17
1146	1117		18
1147	1118		19
1148	1119		20
1149	1120		21
1150	1121		22
1151	1122		23
1152	1123		24
1153	1124
1154	1125		chronic, unremitting or intractable pain such as neuropathic pain;
1155	1126		and
1156	1127		47. “Surgical procedure” means a procedure that is performed
1157	1128		for the purpose of structurally altering th e human body by incision
1158	1129		or destruction of tissues as part of the practice of med icine. This
1159	1130		term includes the diagnostic or therapeutic treatment of conditions
1160	1131		or disease processes by use of instruments such as lasers,
1161	1132		ultrasound, ionizing, radiation, sc alpels, probes or needles that
1162	1133		cause localized alteration or transportation of li ve human tissue by
1163	1134		cutting, burning, vaporizing, freezing, suturing, probing or
1164	1135		manipulating by closed reduction for major dislocations or
1165	1136		fractures, or otherwise altering by any mechanical, thermal, light-
1166	1137		based, electromagnetic or chemical means.
1167	1138		SECTION 2. AMENDATORY 63 O.S. 2021, Section 2 -204, is
1168	1139		amended to read as follows:
1169	1140		Section 2-204. The controlled substances listed in this section
1170	1141		are included in Schedule I and include any material, compound,
1171	1142		mixture or preparatio n that contains any quantity of the following
1172	1143		hallucinogenic substances, their salts, isomers and salts of
1173	1144		isomers, unless specifically excepted, when the existence of these
1174	1145		salts, isomers and salts of isomers is possible within the specific
1175	1146		chemical designation.
1176	1147		A. Any of the following opiates, including their isomers,
1177	1148		esters, ethers, salts, and salts of isomers, esters, and ethers,
1178	1149
1179		-	SB1338 HFLR Page 24
1180		-	BOLD FACE denotes Committee Amendments. 1
	1150	+	ENGR. S. B. NO. 1338 Page 24 1
1181	1151		2
1182	1152		3
1183	1153		4
1184	1154		5
1185	1155		6
1186	1156		7
1187	1157		8
1188	1158		9
1189	1159		10
1190	1160		11
1191	1161		12
1192	1162		13
1193	1163		14
1194	1164		15
1195	1165		16
1196	1166		17
1197	1167		18
1198	1168		19
1199	1169		20
1200	1170		21
1201	1171		22
1202	1172		23
1203	1173		24
1204	1174
1205	1175		unless specifically excepted, when the existence o f these isomers,
1206	1176		esters, ethers, and salts is possible within the specific chemical
1207	1177		designation:
1208	1178		1. Acetylmethadol;
1209	1179		2. Allylprodine;
1210	1180		3. Alphacetylmethadol;
1211	1181		4. Alphameprodine;
1212	1182		5. Alphamethadol;
1213	1183		6. Benzethidine;
1214	1184		7. Betacetylmethadol;
1215	1185		8. Betameprodine;
1216	1186		9. Betamethadol;
1217	1187		10. Betaprodine;
1218	1188		11. Clonitazene;
1219	1189		12. Dextromoramide;
1220	1190		13. Dextrorphan (except its methyl ether);
1221	1191		14. Diampromide;
1222	1192		15. Diethylthiambutene;
1223	1193		16. Dimenoxadol;
1224	1194		17. Dimepheptanol;
1225	1195		18. Dimethylthiambutene;
1226	1196		19. Dioxaphetyl butyrate;
1227	1197		20. Dipipanone;
1228	1198		21. Ethylmethylthiambutene;
1229	1199
1230		-	SB1338 HFLR Page 25
1231		-	BOLD FACE denotes Committee Amendments. 1
	1200	+	ENGR. S. B. NO. 1338 Page 25 1
1232	1201		2
1233	1202		3
1234	1203		4
1235	1204		5
1236	1205		6
1237	1206		7
1238	1207		8
1239	1208		9
1240	1209		10
1241	1210		11
1242	1211		12
1243	1212		13
1244	1213		14
1245	1214		15
1246	1215		16
1247	1216		17
1248	1217		18
1249	1218		19
1250	1219		20
1251	1220		21
1252	1221		22
1253	1222		23
1254	1223		24
1255	1224
1256	1225		22. Etonitazene;
1257	1226		23. Etoxeridine;
1258	1227		24. Furethidine;
1259	1228		25. Hydroxypethidine;
1260	1229		26. Ketobemidone;
1261	1230		27. Levomoramide;
1262	1231		28. Levophenacylmorphan;
1263	1232		29. Morpheridine;
1264	1233		30. Noracymethadol;
1265	1234		31. Norlevorphanol;
1266	1235		32. Normethadone;
1267	1236		33. Norpipanone;
1268	1237		34. Phenadoxone;
1269	1238		35. Phenampromide;
1270	1239		36. Phenomorphan;
1271	1240		37. Phenoperidine;
1272	1241		38. Piritramide;
1273	1242		39. Proheptazine;
1274	1243		40. Properidine;
1275	1244		41. Racemoramide; or
1276	1245		42. Trimeperidine.
1277	1246		B. Any of the following opium derivatives, their salt s,
1278	1247		isomers, and salts of isomers, unless specifical ly excepted, when
1279	1248
1280		-	SB1338 HFLR Page 26
1281		-	BOLD FACE denotes Committee Amendments. 1
	1249	+	ENGR. S. B. NO. 1338 Page 26 1
1282	1250		2
1283	1251		3
1284	1252		4
1285	1253		5
1286	1254		6
1287	1255		7
1288	1256		8
1289	1257		9
1290	1258		10
1291	1259		11
1292	1260		12
1293	1261		13
1294	1262		14
1295	1263		15
1296	1264		16
1297	1265		17
1298	1266		18
1299	1267		19
1300	1268		20
1301	1269		21
1302	1270		22
1303	1271		23
1304	1272		24
1305	1273
1306	1274		the existence of these salts, isomers, and salts of isomers is
1307	1275		possible within the specific chemical designation:
1308	1276		1. Acetorphine;
1309	1277		2. Acetyldihydrocodeine;
1310	1278		3. Benzylmorphine;
1311	1279		4. Codeine methylbromide;
1312	1280		5. Codeine-N-Oxide;
1313	1281		6. Cyprenorphine;
1314	1282		7. Desomorphine;
1315	1283		8. Dihydromorphine;
1316	1284		9. Etorphine;
1317	1285		10. Heroin;
1318	1286		11. Hydromorphinol;
1319	1287		12. Methyldesorphine;
1320	1288		13. Methylhydromorphine;
1321	1289		14. Morphine methylbromide;
1322	1290		15. Morphine methylsulfonate;
1323	1291		16. Morphine-N-Oxide;
1324	1292		17. Myrophine;
1325	1293		18. Nicocodeine;
1326	1294		19. Nicomorphine;
1327	1295		20. Normorphine;
1328	1296		21. Phoclodine;
1329	1297		22. Thebacon;
1330	1298
1331		-	SB1338 HFLR Page 27
1332		-	BOLD FACE denotes Committee Amendments. 1
	1299	+	ENGR. S. B. NO. 1338 Page 27 1
1333	1300		2
1334	1301		3
1335	1302		4
1336	1303		5
1337	1304		6
1338	1305		7
1339	1306		8
1340	1307		9
1341	1308		10
1342	1309		11
1343	1310		12
1344	1311		13
1345	1312		14
1346	1313		15
1347	1314		16
1348	1315		17
1349	1316		18
1350	1317		19
1351	1318		20
1352	1319		21
1353	1320		22
1354	1321		23
1355	1322		24
1356	1323
1357	1324		23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide
1358	1325		(Acetyl fentanyl);
1359	1326		24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide
1360	1327		(Crotonyl fentanyl);
1361	1328		25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
1362	1329		furancarboxamide (Furanyl fentanyl);
1363	1330		26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
1364	1331		27. N-(1-phenethylpiperidin-4-yl)-N-
1365	1332		phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or
1366	1333		28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide
1367	1334		(Butyrl fentanyl).
1368	1335		C. Any material, compound, mixture, or preparation which
1369	1336		contains any quantity of the following hallucinogenic substances,
1370	1337		their salts, isomers, and salts of is omers, unless specifically
1371	1338		excepted, when the existence of these salts, isomers, and salts of
1372	1339		isomers is possible within the specific chemical designation:
1373	1340		1. Methcathinone;
1374	1341		2. 3, 4-methylenedioxy amphetamine;
1375	1342		3. 3, 4-methylenedioxy methamphetamine;
1376	1343		4. 5-methoxy-3, 4-methylenedioxy amphetamine ;
1377	1344		5. 3, 4, 5-trimethoxy amphetamine;
1378	1345		6. Bufotenine;
1379	1346		7. Diethyltryptamine;
1380	1347		8. Dimethyltryptamine;
1381	1348
1382		-	SB1338 HFLR Page 28
1383		-	BOLD FACE denotes Committee Amendments. 1
	1349	+	ENGR. S. B. NO. 1338 Page 28 1
1384	1350		2
1385	1351		3
1386	1352		4
1387	1353		5
1388	1354		6
1389	1355		7
1390	1356		8
1391	1357		9
1392	1358		10
1393	1359		11
1394	1360		12
1395	1361		13
1396	1362		14
1397	1363		15
1398	1364		16
1399	1365		17
1400	1366		18
1401	1367		19
1402	1368		20
1403	1369		21
1404	1370		22
1405	1371		23
1406	1372		24
1407	1373
1408	1374		9. 4-methyl-2, 5-dimethoxyamphetamine;
1409	1375		10. Ibogaine;
1410	1376		11. Lysergic acid diethylamide;
1411	1377		12. Marijuana;
1412	1378		13. Mescaline;
1413	1379		14. N-benzylpiperazine;
1414	1380		15. N-ethyl-3-piperidyl benzilate;
1415	1381		16. N-methyl-3-piperidyl benzilate;
1416	1382		17. Psilocybin;
1417	1383		18. Psilocyn;
1418	1384		19. 2, 5 dimethoxyamphetamine;
1419	1385		20. 4 Bromo-2, 5-dimethoxyamphetamine;
1420	1386		21. 4 methoxyamphetamine;
1421	1387		22. Cyclohexamine;
1422	1388		23. Salvia Divinorum;
1423	1389		24. Salvinorin A;
1424	1390		25. Thiophene Analog of Phencyclidine. Also known as: 1-(1-(2-
1425	1391		thienyl) cyclohexyl) piperidine; 2 -Thienyl Analog of Phencyclidine;
1426	1392		TPCP, TCP;
1427	1393		26. Phencyclidine (PCP);
1428	1394		27. Pyrrolidine Analog for Phencyclidine. A lso known as 1-(1-
1429	1395		Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;
1430	1396		28. 1-(3-trifluoromethylphenyl) piperazine;
1431	1397		29. Flunitrazepam;
1432	1398
1433		-	SB1338 HFLR Page 29
1434		-	BOLD FACE denotes Committee Amendments. 1
	1399	+	ENGR. S. B. NO. 1338 Page 29 1
1435	1400		2
1436	1401		3
1437	1402		4
1438	1403		5
1439	1404		6
1440	1405		7
1441	1406		8
1442	1407		9
1443	1408		10
1444	1409		11
1445	1410		12
1446	1411		13
1447	1412		14
1448	1413		15
1449	1414		16
1450	1415		17
1451	1416		18
1452	1417		19
1453	1418		20
1454	1419		21
1455	1420		22
1456	1421		23
1457	1422		24
1458	1423
1459	1424		30. B-hydroxy-amphetamine;
1460	1425		31. B-ketoamphetamine;
1461	1426		32. 2,5-dimethoxy-4-nitroamphetamine;
1462	1427		33. 2,5-dimethoxy-4-bromophenethylamine;
1463	1428		34. 2,5-dimethoxy-4-chlorophenethylamine;
1464	1429		35. 2,5-dimethoxy-4-iodoamphetamine;
1465	1430		36. 2,5-dimethoxy-4-iodophenethylamine;
1466	1431		37. 2,5-dimethoxy-4-methylphenethylamine;
1467	1432		38. 2,5-dimethoxy-4-ethylphenethylamine;
1468	1433		39. 2,5-dimethoxy-4-fluorophenethylamine;
1469	1434		40. 2,5-dimethoxy-4-nitrophenethylamine;
1470	1435		41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
1471	1436		42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
1472	1437		43. 2,5-dimethoxy-4-propylthio-phenethylamine;
1473	1438		44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine;
1474	1439		45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
1475	1440		46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
1476	1441		47. 5-methoxy-N, N-dimethyltryptamine;
1477	1442		48. N-methyltryptamine;
1478	1443		49. A-ethyltryptamine;
1479	1444		50. A-methyltryptamine;
1480	1445		51. N, N-diethyltryptamine;
1481	1446		52. N, N-diisopropyltryptamine;
1482	1447		53. N, N-dipropyltryptamine;
1483	1448
1484		-	SB1338 HFLR Page 30
1485		-	BOLD FACE denotes Committee Amendments. 1
	1449	+	ENGR. S. B. NO. 1338 Page 30 1
1486	1450		2
1487	1451		3
1488	1452		4
1489	1453		5
1490	1454		6
1491	1455		7
1492	1456		8
1493	1457		9
1494	1458		10
1495	1459		11
1496	1460		12
1497	1461		13
1498	1462		14
1499	1463		15
1500	1464		16
1501	1465		17
1502	1466		18
1503	1467		19
1504	1468		20
1505	1469		21
1506	1470		22
1507	1471		23
1508	1472		24
1509	1473
1510	1474		54. 5-methoxy-a-methyltryptamine;
1511	1475		55. 4-hydroxy-N, N-diethyltryptamine;
1512	1476		56. 4-hydroxy-N, N-diisopropyltryptamine;
1513	1477		57. 5-methoxy-N, N-diisopropyltryptamine;
1514	1478		58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
1515	1479		59. 3,4-Methylenedioxymethcathinone (Methylone);
1516	1480		60. 3,4-Methylenedioxypyrovaler one (MDPV);
1517	1481		61. 4-Methylmethcathinone (Mephedrone);
1518	1482		62. 4-methoxymethcathinone;
1519	1483		63. 4-Fluoromethcathinone;
1520	1484		64. 3-Fluoromethcathinone;
1521	1485		65. 1-(8-bromobenzo 1,2-b;4,5-b’ difuran-4-yl)-2-aminopropane;
1522	1486		66. 2,5-Dimethoxy-4-chloroamphetamine;
1523	1487		67. 4-Methylethcathinone;
1524	1488		68. Pyrovalerone;
1525	1489		69. N,N-diallyl-5-methoxytryptamine;
1526	1490		70. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
1527	1491		71. B-keto-N-Methylbenzodioxolylbutanamine (Butylon e);
1528	1492		72. B-keto-Methylbenzodioxolylpentanamine (Pentylone);
1529	1493		73. Alpha-Pyrrolidinopentiophenone;
1530	1494		74. 4-Fluoroamphetamine;
1531	1495		75. Pentedrone;
1532	1496		76. 4’-Methyl-a-pyrrolidinohexaphenone;
1533	1497		77. 2,5-dimethoxy-4-(n)-propylphenethylamine;
1534	1498
1535		-	SB1338 HFLR Page 31
1536		-	BOLD FACE denotes Committee Amendments. 1
	1499	+	ENGR. S. B. NO. 1338 Page 31 1
1537	1500		2
1538	1501		3
1539	1502		4
1540	1503		5
1541	1504		6
1542	1505		7
1543	1506		8
1544	1507		9
1545	1508		10
1546	1509		11
1547	1510		12
1548	1511		13
1549	1512		14
1550	1513		15
1551	1514		16
1552	1515		17
1553	1516		18
1554	1517		19
1555	1518		20
1556	1519		21
1557	1520		22
1558	1521		23
1559	1522		24
1560	1523
1561	1524		78. 2,5-dimethoxyphenethylamine;
1562	1525		79. 1,4-Dibenzylpiperazine;
1563	1526		80. N,N-Dimethylamphetamine;
1564	1527		81. 4-Fluoromethamphetamine;
1565	1528		82. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
1566	1529		(25C-NBOMe);
1567	1530		83. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
1568	1531		(25I-NBOMe);
1569	1532		84. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine
1570	1533		(25B-NBOMe);
1571	1534		85. 1-(4-Fluorophenyl)piperazine;
1572	1535		86. Methoxetamine;
1573	1536		87. 3,4-dichloro-N[2-dimethylamino)cyclohexyl] -N-
1574	1537		methylbenzamide;
1575	1538		88. N-ethyl hexadrone;
1576	1539		89. Isopropyl-U-47700;
1577	1540		90. Para-fluorobutyrl fentanyl;
1578	1541		91. Fluoro isobutryrl fentanyl;
1579	1542		92. 3-Hydroxy Phencyclidine (PCP); or
1580	1543		93. 3-methoxy Phencyclidine (PCP); or
1581	1544		94. Tetrahydrocannabinol s. For the purposes of this paragraph,
1582	1545		tetrahydrocannabinols:
1583	1546		a. includes:
1584	1547
1585		-	SB1338 HFLR Page 32
1586		-	BOLD FACE denotes Committee Amendments. 1
	1548	+	ENGR. S. B. NO. 1338 Page 32 1
1587	1549		2
1588	1550		3
1589	1551		4
1590	1552		5
1591	1553		6
1592	1554		7
1593	1555		8
1594	1556		9
1595	1557		10
1596	1558		11
1597	1559		12
1598	1560		13
1599	1561		14
1600	1562		15
1601	1563		16
1602	1564		17
1603	1565		18
1604	1566		19
1605	1567		20
1606	1568		21
1607	1569		22
1608	1570		23
1609	1571		24
1610	1572
1611	1573		(1) delta-8 tetrahydrocannabinol in a concentration
1612	1574		of more than two percent (2%), or
1613	1575		(2) except as provided by divisi on 2 of subparagraph
1614	1576		b of this paragraph, any other
1615	1577		tetrahydrocannabinols in any concentration , and
1616	1578		b. does not include:
1617	1579		(1) delta-8 tetrahydrocannabinol in a concentration
1618	1580		of not more than two percent (2%), or
1619	1581		(2) any tetrahydrocannabinols specifically excepted
1620	1582		or listed in a different schedule including but
1621	1583		not limited to delta-9 tetrahydrocannabinol as
1622	1584		provided under Section 2 -208 of this title.
1623	1585		D. Unless specifically excep ted or unless listed in a different
1624	1586		schedule, any material, compound, mixture, or preparation which
1625	1587		contains any quantity of the following substances having stimulant
1626	1588		or depressant effect on the central nervous system:
1627	1589		1. Fenethylline;
1628	1590		2. Mecloqualone;
1629	1591		3. N-ethylamphetamine;
1630	1592		4. Methaqualone;
1631	1593		5. Gamma-Hydroxybutyric Acid, also know n as GHB, gamma-
1632	1594		hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium
1633	1595		oxybate, and sodium oxybutyrate;
1634	1596
1635		-	SB1338 HFLR Page 33
1636		-	BOLD FACE denotes Committee Amendments. 1
	1597	+	ENGR. S. B. NO. 1338 Page 33 1
1637	1598		2
1638	1599		3
1639	1600		4
1640	1601		5
1641	1602		6
1642	1603		7
1643	1604		8
1644	1605		9
1645	1606		10
1646	1607		11
1647	1608		12
1648	1609		13
1649	1610		14
1650	1611		15
1651	1612		16
1652	1613		17
1653	1614		18
1654	1615		19
1655	1616		20
1656	1617		21
1657	1618		22
1658	1619		23
1659	1620		24
1660	1621
1661	1622		6. Gamma-Butyrolactone (GBL) as packaged, marketed,
1662	1623		manufactured or promoted for human consumption, with the exception
1663	1624		of legitimate food a dditive and manufacturing purposes;
1664	1625		7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or
1665	1626		manufactured for human consumption, with the exception of legitimate
1666	1627		food additive and manufacturing purposes;
1667	1628		8. Gamma Valerolactone (GVL) as packaged, marketed , or
1668	1629		manufactured for human consumption, with the exception of legitimate
1669	1630		food additive and manufacturing purposes;
1670	1631		9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed,
1671	1632		manufactured, or promoted for human consumption with the exception
1672	1633		of legitimate manufacturing purposes; or
1673	1634		10. N-ethylpentylone.
1674	1635		E. 1. The following industrial uses of Gamma -Butyrolactone,
1675	1636		Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol ar e
1676	1637		excluded from all schedules of controlled substances under this
1677	1638		title:
1678	1639		a. pesticides,
1679	1640		b. photochemical etching,
1680	1641		c. electrolytes of small batteries or capacitors,
1681	1642		d. viscosity modifiers in polyurethane,
1682	1643		e. surface etching of metal coated plastics,
1683	1644		f. organic paint disbursements for water soluble inks,
1684	1645
1685		-	SB1338 HFLR Page 34
1686		-	BOLD FACE denotes Committee Amendments. 1
	1646	+	ENGR. S. B. NO. 1338 Page 34 1
1687	1647		2
1688	1648		3
1689	1649		4
1690	1650		5
1691	1651		6
1692	1652		7
1693	1653		8
1694	1654		9
1695	1655		10
1696	1656		11
1697	1657		12
1698	1658		13
1699	1659		14
1700	1660		15
1701	1661		16
1702	1662		17
1703	1663		18
1704	1664		19
1705	1665		20
1706	1666		21
1707	1667		22
1708	1668		23
1709	1669		24
1710	1670
1711	1671		g. pH regulators in the dyeing o f wool and polyamide
1712	1672		fibers,
1713	1673		h. foundry chemistry as a catalyst during curing,
1714	1674		i. curing agents in many coating systems based on
1715	1675		urethanes and amides,
1716	1676		j. additives and flavorin g agents in food, confectionary,
1717	1677		and beverage products,
1718	1678		k. synthetic fiber and c lothing production,
1719	1679		l. tetrahydrofuran production,
1720	1680		m. gamma butyrolactone production,
1721	1681		n. polybutylene terephthalate resin production,
1722	1682		o. polyester raw materials for polyurethan e elastomers
1723	1683		and foams,
1724	1684		p. coating resin raw material, and
1725	1685		q. as an intermediate in the manufacture of other
1726	1686		chemicals and pharmaceuticals.
1727	1687		2. At the request of any person, the Director may exempt any
1728	1688		other product containing Gamma -Butyrolactone, Gamma Hy droxyvalerate,
1729	1689		Gamma Valerolactone, or 1,4 Butanediol from being included as a
1730	1690		Schedule I controlled substance if such product is labeled,
1731	1691		marketed, manufactured and distributed for legitimate industrial use
1732	1692		in a manner that reduces or eliminates the likel ihood of abuse.
1733	1693
1734		-	SB1338 HFLR Page 35
1735		-	BOLD FACE denotes Committee Amendments. 1
	1694	+	ENGR. S. B. NO. 1338 Page 35 1
1736	1695		2
1737	1696		3
1738	1697		4
1739	1698		5
1740	1699		6
1741	1700		7
1742	1701		8
1743	1702		9
1744	1703		10
1745	1704		11
1746	1705		12
1747	1706		13
1748	1707		14
1749	1708		15
1750	1709		16
1751	1710		17
1752	1711		18
1753	1712		19
1754	1713		20
1755	1714		21
1756	1715		22
1757	1716		23
1758	1717		24
1759	1718
1760	1719		3. In making a determination regarding an industrial product,
1761	1720		the Director, after notice and hearing, shall consider the
1762	1721		following:
1763	1722		a. the history and current pattern of abuse,
1764	1723		b. the name and labeling of the product,
1765	1724		c. the intended manner of distribution, advertising and
1766	1725		promotion of the product, and
1767	1726		d. other factors as may be relevant to and consistent
1768	1727		with the public health and safety.
1769	1728		4. The hearing shall be held in accordance with the procedures
1770	1729		of the Administrative Procedures Act.
1771	1730		F. Any material, compound, mixture, or preparation, whether
1772	1731		produced directly or indirectly from a substance of vegetable origin
1773	1732		or independently by means of chemical synthesis, or by a combination
1774	1733		of extraction and chemical synthesis, that contains any q uantity of
1775	1734		the following substances, or that contains any of their salts,
1776	1735		isomers, and salts of isomers when the existence of these salts,
1777	1736		isomers, and salts of isomers is possible within the specific
1778	1737		chemical designation:
1779	1738		1. JWH-004;
1780	1739		2. JWH-007;
1781	1740		3. JWH-009;
1782	1741		4. JWH-015;
1783	1742		5. JWH-016;
1784	1743
1785		-	SB1338 HFLR Page 36
1786		-	BOLD FACE denotes Committee Amendments. 1
	1744	+	ENGR. S. B. NO. 1338 Page 36 1
1787	1745		2
1788	1746		3
1789	1747		4
1790	1748		5
1791	1749		6
1792	1750		7
1793	1751		8
1794	1752		9
1795	1753		10
1796	1754		11
1797	1755		12
1798	1756		13
1799	1757		14
1800	1758		15
1801	1759		16
1802	1760		17
1803	1761		18
1804	1762		19
1805	1763		20
1806	1764		21
1807	1765		22
1808	1766		23
1809	1767		24
1810	1768
1811	1769		6. JWH-018;
1812	1770		7. JWH-019;
1813	1771		8. JWH-020;
1814	1772		9. JWH-030;
1815	1773		10. JWH-046;
1816	1774		11. JWH-047;
1817	1775		12. JWH-048;
1818	1776		13. JWH-049;
1819	1777		14. JWH-050;
1820	1778		15. JWH-070;
1821	1779		16. JWH-071;
1822	1780		17. JWH-072;
1823	1781		18. JWH-073;
1824	1782		19. JWH-076;
1825	1783		20. JWH-079;
1826	1784		21. JWH-080;
1827	1785		22. JWH-081;
1828	1786		23. JWH-082;
1829	1787		24. JWH-094;
1830	1788		25. JWH-096;
1831	1789		26. JWH-098;
1832	1790		27. JWH-116;
1833	1791		28. JWH-120;
1834	1792		29. JWH-122;
1835	1793
1836		-	SB1338 HFLR Page 37
1837		-	BOLD FACE denotes Committee Amendments. 1
	1794	+	ENGR. S. B. NO. 1338 Page 37 1
1838	1795		2
1839	1796		3
1840	1797		4
1841	1798		5
1842	1799		6
1843	1800		7
1844	1801		8
1845	1802		9
1846	1803		10
1847	1804		11
1848	1805		12
1849	1806		13
1850	1807		14
1851	1808		15
1852	1809		16
1853	1810		17
1854	1811		18
1855	1812		19
1856	1813		20
1857	1814		21
1858	1815		22
1859	1816		23
1860	1817		24
1861	1818
1862	1819		30. JWH-145;
1863	1820		31. JWH-146;
1864	1821		32. JWH-147;
1865	1822		33. JWH-148;
1866	1823		34. JWH-149;
1867	1824		35. JWH-150;
1868	1825		36. JWH-156;
1869	1826		37. JWH-167;
1870	1827		38. JWH-175;
1871	1828		39. JWH-180;
1872	1829		40. JWH-181;
1873	1830		41. JWH-182;
1874	1831		42. JWH-184;
1875	1832		43. JWH-185;
1876	1833		44. JWH-189;
1877	1834		45. JWH-192;
1878	1835		46. JWH-193;
1879	1836		47. JWH-194;
1880	1837		48. JWH-195;
1881	1838		49. JWH-196;
1882	1839		50. JWH-197;
1883	1840		51. JWH-198;
1884	1841		52. JWH-199;
1885	1842		53. JWH-200;
1886	1843
1887		-	SB1338 HFLR Page 38
1888		-	BOLD FACE denotes Committee Amendments. 1
	1844	+	ENGR. S. B. NO. 1338 Page 38 1
1889	1845		2
1890	1846		3
1891	1847		4
1892	1848		5
1893	1849		6
1894	1850		7
1895	1851		8
1896	1852		9
1897	1853		10
1898	1854		11
1899	1855		12
1900	1856		13
1901	1857		14
1902	1858		15
1903	1859		16
1904	1860		17
1905	1861		18
1906	1862		19
1907	1863		20
1908	1864		21
1909	1865		22
1910	1866		23
1911	1867		24
1912	1868
1913	1869		54. JWH-201;
1914	1870		55. JWH-202;
1915	1871		56. JWH-203;
1916	1872		57. JWH-204;
1917	1873		58. JWH-205;
1918	1874		59. JWH-206;
1919	1875		60. JWH-207;
1920	1876		61. JWH-208;
1921	1877		62. JWH-209;
1922	1878		63. JWH-210;
1923	1879		64. JWH-211;
1924	1880		65. JWH-212;
1925	1881		66. JWH-213;
1926	1882		67. JWH-234;
1927	1883		68. JWH-235;
1928	1884		69. JWH-236;
1929	1885		70. JWH-237;
1930	1886		71. JWH-239;
1931	1887		72. JWH-240;
1932	1888		73. JWH-241;
1933	1889		74. JWH-242;
1934	1890		75. JWH-243;
1935	1891		76. JWH-244;
1936	1892		77. JWH-245;
1937	1893
1938		-	SB1338 HFLR Page 39
1939		-	BOLD FACE denotes Committee Amendments. 1
	1894	+	ENGR. S. B. NO. 1338 Page 39 1
1940	1895		2
1941	1896		3
1942	1897		4
1943	1898		5
1944	1899		6
1945	1900		7
1946	1901		8
1947	1902		9
1948	1903		10
1949	1904		11
1950	1905		12
1951	1906		13
1952	1907		14
1953	1908		15
1954	1909		16
1955	1910		17
1956	1911		18
1957	1912		19
1958	1913		20
1959	1914		21
1960	1915		22
1961	1916		23
1962	1917		24
1963	1918
1964	1919		78. JWH-246;
1965	1920		79. JWH-248;
1966	1921		80. JWH-249;
1967	1922		81. JWH-250;
1968	1923		82. JWH-251;
1969	1924		83. JWH-252;
1970	1925		84. JWH-253;
1971	1926		85. JWH-262;
1972	1927		86. JWH-292;
1973	1928		87. JWH-293;
1974	1929		88. JWH-302;
1975	1930		89. JWH-303;
1976	1931		90. JWH-304;
1977	1932		91. JWH-305;
1978	1933		92. JWH-306;
1979	1934		93. JWH-307;
1980	1935		94. JWH-308;
1981	1936		95. JWH-311;
1982	1937		96. JWH-312;
1983	1938		97. JWH-313;
1984	1939		98. JWH-314;
1985	1940		99. JWH-315;
1986	1941		100. JWH-316;
1987	1942		101. JWH-346;
1988	1943
1989		-	SB1338 HFLR Page 40
1990		-	BOLD FACE denotes Committee Amendments. 1
	1944	+	ENGR. S. B. NO. 1338 Page 40 1
1991	1945		2
1992	1946		3
1993	1947		4
1994	1948		5
1995	1949		6
1996	1950		7
1997	1951		8
1998	1952		9
1999	1953		10
2000	1954		11
2001	1955		12
2002	1956		13
2003	1957		14
2004	1958		15
2005	1959		16
2006	1960		17
2007	1961		18
2008	1962		19
2009	1963		20
2010	1964		21
2011	1965		22
2012	1966		23
2013	1967		24
2014	1968
2015	1969		102. JWH-348;
2016	1970		103. JWH-363;
2017	1971		104. JWH-364;
2018	1972		105. JWH-365;
2019	1973		106. JWH-367;
2020	1974		107. JWH-368;
2021	1975		108. JWH-369;
2022	1976		109. JWH-370;
2023	1977		110. JWH-371;
2024	1978		111. JWH-373;
2025	1979		112. JWH-386;
2026	1980		113. JWH-387;
2027	1981		114. JWH-392;
2028	1982		115. JWH-394;
2029	1983		116. JWH-395;
2030	1984		117. JWH-397;
2031	1985		118. JWH-398;
2032	1986		119. JWH-399;
2033	1987		120. JWH-400;
2034	1988		121. JWH-412;
2035	1989		122. JWH-413;
2036	1990		123. JWH-414;
2037	1991		124. JWH-415;
2038	1992		125. CP-55, 940;
2039	1993
2040		-	SB1338 HFLR Page 41
2041		-	BOLD FACE denotes Committee Amendments. 1
	1994	+	ENGR. S. B. NO. 1338 Page 41 1
2042	1995		2
2043	1996		3
2044	1997		4
2045	1998		5
2046	1999		6
2047	2000		7
2048	2001		8
2049	2002		9
2050	2003		10
2051	2004		11
2052	2005		12
2053	2006		13
2054	2007		14
2055	2008		15
2056	2009		16
2057	2010		17
2058	2011		18
2059	2012		19
2060	2013		20
2061	2014		21
2062	2015		22
2063	2016		23
2064	2017		24
2065	2018
2066	2019		126. CP-47, 497;
2067	2020		127. HU-210;
2068	2021		128. HU-211;
2069	2022		129. WIN-55, 212-2;
2070	2023		130. AM-2201;
2071	2024		131. AM-2233;
2072	2025		132. JWH-018 adamantyl-carboxamide;
2073	2026		133. AKB48;
2074	2027		134. JWH-122 N-(4-pentenyl)analog;
2075	2028		135. MAM2201;
2076	2029		136. URB597;
2077	2030		137. URB602;
2078	2031		138. URB754;
2079	2032		139. UR144;
2080	2033		140. XLR11;
2081	2034		141. A-796,260;
2082	2035		142. STS-135;
2083	2036		143. AB-FUBINACA;
2084	2037		144. AB-PINACA;
2085	2038		145. PB-22;
2086	2039		146. AKB48 N-5-Fluorpentyl;
2087	2040		147. AM1248;
2088	2041		148. FUB-PB-22;
2089	2042		149. ADB-FUBINACA;
2090	2043
2091		-	SB1338 HFLR Page 42
2092		-	BOLD FACE denotes Committee Amendments. 1
	2044	+	ENGR. S. B. NO. 1338 Page 42 1
2093	2045		2
2094	2046		3
2095	2047		4
2096	2048		5
2097	2049		6
2098	2050		7
2099	2051		8
2100	2052		9
2101	2053		10
2102	2054		11
2103	2055		12
2104	2056		13
2105	2057		14
2106	2058		15
2107	2059		16
2108	2060		17
2109	2061		18
2110	2062		19
2111	2063		20
2112	2064		21
2113	2065		22
2114	2066		23
2115	2067		24
2116	2068
2117	2069		150. BB-22;
2118	2070		151. 5-Fluoro PB-22; or
2119	2071		152. 5-Fluoro AKB-48.
2120	2072		G. In addition to those substances listed in subsection F of
2121	2073		this section, unless specifically excepted or unless listed in
2122	2074		another schedule, any material, com pound, mixture, or preparation
2123	2075		which contains any quantity of a synthetic cannabinoid found to be
2124	2076		in any of the following chemical groups:
2125	2077		1. Naphthoylindoles: any compound c ontaining a 3-(1-
2126	2078		naphthoyl)indole structure with or without substitution at the
2127	2079		nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
2128	2080		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
2129	2081		(N-methyl-2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1-(N-methyl-
2130	2082		2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
2131	2083		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
2132	2084		halophenyl group, whether or not further substituted on the indole
2133	2085		ring to any extent, and whether or not substi tuted on the naphthyl
2134	2086		ring to any extent. Napht hoylindoles include, but are not limited
2135	2087		to:
2136	2088		a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH -
2137	2089		200),
2138	2090		b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
2139	2091		c. 1-pentyl-3-(1-naphthoyl)indole (JWH -018),
2140	2092		d. 1-butyl-3-(1-naphthoyl)indole (JWH -073),
2141	2093
2142		-	SB1338 HFLR Page 43
2143		-	BOLD FACE denotes Committee Amendments. 1
	2094	+	ENGR. S. B. NO. 1338 Page 43 1
2144	2095		2
2145	2096		3
2146	2097		4
2147	2098		5
2148	2099		6
2149	2100		7
2150	2101		8
2151	2102		9
2152	2103		10
2153	2104		11
2154	2105		12
2155	2106		13
2156	2107		14
2157	2108		15
2158	2109		16
2159	2110		17
2160	2111		18
2161	2112		19
2162	2113		20
2163	2114		21
2164	2115		22
2165	2116		23
2166	2117		24
2167	2118
2168	2119		e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081),
2169	2120		f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH -015),
2170	2121		g. 1-hexyl-3-(1-naphthoyl)indole (JWH -019),
2171	2122		h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH -122),
2172	2123		i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH -210),
2173	2124		j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398),
2174	2125		k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH -007),
2175	2126		l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH -164),
2176	2127		m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
2177	2128		(JWH-098),
2178	2129		n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH -412),
2179	2130		o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
2180	2131		naphthoyl)indole (AM -1220),
2181	2132		p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
2182	2133		(MAM-2201), or
2183	2134		q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232);
2184	2135		2. Naphthylmethylindoles: any compound containing a 1H -indol-3-
2185	2136		yl-(1-naphthyl)methane structure with or without substitution at the
2186	2137		nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
2187	2138		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-
2188	2139		(N-methyl-2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-
2189	2140		2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
2190	2141		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
2191	2142		halophenyl group, whether or not further substitu ted on the indole
2192	2143
2193		-	SB1338 HFLR Page 44
2194		-	BOLD FACE denotes Committee Amendments. 1
	2144	+	ENGR. S. B. NO. 1338 Page 44 1
2195	2145		2
2196	2146		3
2197	2147		4
2198	2148		5
2199	2149		6
2200	2150		7
2201	2151		8
2202	2152		9
2203	2153		10
2204	2154		11
2205	2155		12
2206	2156		13
2207	2157		14
2208	2158		15
2209	2159		16
2210	2160		17
2211	2161		18
2212	2162		19
2213	2163		20
2214	2164		21
2215	2165		22
2216	2166		23
2217	2167		24
2218	2168
2219	2169		ring to any extent, and whether or not substituted on the napht hyl
2220	2170		ring to any extent. Naphthylmethylindoles include, but are not
2221	2171		limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH -175);
2222	2172		3. Naphthoylpyrroles: any compound containi ng a 3-(1-
2223	2173		naphthoyl)pyrrole structure with or without substitution at the
2224	2174		nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
2225	2175		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
2226	2176		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
2227	2177		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
2228	2178		morpholinyl)methyl, (t etrahydropyran-4-yl)methyl, 1-methylazepanyl,
2229	2179		phenyl, or halophenyl group, whether or not further substituted on
2230	2180		the pyrrole ring to any extent, and whether or not substituted on
2231	2181		the naphthyl group to any extent. Naphthoylpyrroles include, but
2232	2182		are not limited to:
2233	2183		a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH -147),
2234	2184		b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole
2235	2185		(JWH-370),
2236	2186		c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH -030), or
2237	2187		d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH -147);
2238	2188		4. Naphthylideneindenes: any compound containing a 1-(1-
2239	2189		naphthylmethylene)indene structure with or without substitution at
2240	2190		the 3-position of the indene ring by an alkyl, haloalkyl,
2241	2191		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
2242	2192		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
2243	2193
2244		-	SB1338 HFLR Page 45
2245		-	BOLD FACE denotes Committee Amendments. 1
	2194	+	ENGR. S. B. NO. 1338 Page 45 1
2246	2195		2
2247	2196		3
2248	2197		4
2249	2198		5
2250	2199		6
2251	2200		7
2252	2201		8
2253	2202		9
2254	2203		10
2255	2204		11
2256	2205		12
2257	2206		13
2258	2207		14
2259	2208		15
2260	2209		16
2261	2210		17
2262	2211		18
2263	2212		19
2264	2213		20
2265	2214		21
2266	2215		22
2267	2216		23
2268	2217		24
2269	2218
2270	2219		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
2271	2220		morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
2272	2221		phenyl, or halophenyl group, whether or not further substituted on
2273	2222		the indene group to any extent, and w hether or not substituted on
2274	2223		the naphthyl group to any extent. Naphthylmethylindenes include,
2275	2224		but are not limited to, (1 -[(3-pentyl)-1H-inden-1-
2276	2225		ylidene)methyl]naphthalene (JWH-176);
2277	2226		5. Phenylacetylindoles: any compound containing a 3 -
2278	2227		phenylacetylindole s tructure with or without substitution at the
2279	2228		nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
2280	2229		alkenyl, cycloalkylmethyl, cycloalkylethyl, be nzyl, halobenzyl, 1-
2281	2230		(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-
2282	2231		2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
2283	2232		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
2284	2233		halophenyl group, whether or not further substitute d on the indole
2285	2234		ring to any extent, and whether or not substituted on the phenyl
2286	2235		ring to any extent. Phenylacetylindoles include, but are not
2287	2236		limited to:
2288	2237		a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH -250),
2289	2238		b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
2290	2239		(RCS-8),
2291	2240		c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH -203),
2292	2241		d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251),
2293	2242		e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH -201), or
2294	2243
2295		-	SB1338 HFLR Page 46
2296		-	BOLD FACE denotes Committee Amendments. 1
	2244	+	ENGR. S. B. NO. 1338 Page 46 1
2297	2245		2
2298	2246		3
2299	2247		4
2300	2248		5
2301	2249		6
2302	2250		7
2303	2251		8
2304	2252		9
2305	2253		10
2306	2254		11
2307	2255		12
2308	2256		13
2309	2257		14
2310	2258		15
2311	2259		16
2312	2260		17
2313	2261		18
2314	2262		19
2315	2263		20
2316	2264		21
2317	2265		22
2318	2266		23
2319	2267		24
2320	2268
2321	2269		f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH -302);
2322	2270		6. Cyclohexylphenols: any compound containing a 2-(3-
2323	2271		hydroxycyclohexyl)phenol structure with or without substitut ion at
2324	2272		the 5-position of the phenolic ring by an alkyl, haloalkyl,
2325	2273		cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
2326	2274		halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
2327	2275		morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
2328	2276		morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl,
2329	2277		phenyl, or halophenyl group, and whether or not further substituted
2330	2278		on the cyclohexyl ring to any extent. Cyclohexylphenols include,
2331	2279		but are not limited to:
2332	2280		a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
2333	2281		hydroxycyclohexyl]-phenol (CP-47,497),
2334	2282		b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
2335	2283		phenol (cannabicyclohexanol; CP -47,497 C8 homologue),
2336	2284		or
2337	2285		c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
2338	2286		hydroxypropyl)cyclohexyl] -phenol (CP 55, 940);
2339	2287		7. Benzoylindoles: any compound containing a 3 -(benzoyl)indole
2340	2288		structure with or without substitution at the nitrogen atom of the
2341	2289		indole ring by an alkyl, h aloalkyl, cyanoalkyl, alkenyl,
2342	2290		cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
2343	2291		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-2-
2344	2292		pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
2345	2293
2346		-	SB1338 HFLR Page 47
2347		-	BOLD FACE denotes Committee Amendments. 1
	2294	+	ENGR. S. B. NO. 1338 Page 47 1
2348	2295		2
2349	2296		3
2350	2297		4
2351	2298		5
2352	2299		6
2353	2300		7
2354	2301		8
2355	2302		9
2356	2303		10
2357	2304		11
2358	2305		12
2359	2306		13
2360	2307		14
2361	2308		15
2362	2309		16
2363	2310		17
2364	2311		18
2365	2312		19
2366	2313		20
2367	2314		21
2368	2315		22
2369	2316		23
2370	2317		24
2371	2318
2372	2319		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
2373	2320		halophenyl group, whether or not further substituted on the indole
2374	2321		ring to any extent, and whether or not substituted on the phenyl
2375	2322		group to any extent. Benzoylindoles include, but are not limited
2376	2323		to:
2377	2324		a. 1-pentyl-3-(4-methoxybenzoyl)indol e (RCS-4),
2378	2325		b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
2379	2326		methoxybenzoyl)indole (Pravadoline or WIN 48 , 098),
2380	2327		c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM -694),
2381	2328		d. 1-pentyl-3-(2-iodobenzoyl)indole (AM -679), or
2382	2329		e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
2383	2330		iodobenzoyl)indole (AM-2233);
2384	2331		8. Cyclopropoylindoles: Any compound containing a 3 -
2385	2332		(cyclopropoyl)indole structure with substitution at the nitrogen
2386	2333		atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
2387	2334		cycloalkylmethyl, cycloalkylethyl, ben zyl, halobenzyl, 1-(N-methyl-
2388	2335		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-2-
2389	2336		pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
2390	2337		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
2391	2338		halophenyl group, whether or not further substituted in the indole
2392	2339		ring to any extent and whether or not substituted in the
2393	2340		cyclopropoyl ring to any ex tent. Cyclopropoylindoles include, but
2394	2341		are not limited to:
2395	2342
2396		-	SB1338 HFLR Page 48
2397		-	BOLD FACE denotes Committee Amendments. 1
	2343	+	ENGR. S. B. NO. 1338 Page 48 1
2398	2344		2
2399	2345		3
2400	2346		4
2401	2347		5
2402	2348		6
2403	2349		7
2404	2350		8
2405	2351		9
2406	2352		10
2407	2353		11
2408	2354		12
2409	2355		13
2410	2356		14
2411	2357		15
2412	2358		16
2413	2359		17
2414	2360		18
2415	2361		19
2416	2362		20
2417	2363		21
2418	2364		22
2419	2365		23
2420	2366		24
2421	2367
2422	2368		a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole
2423	2369		(UR-144),
2424	2370		b. 1-(5-chloropentyl)-3-(2,2,3,3-
2425	2371		tetramethylcyclopropoyl)indole (5Cl-UR-144), or
2426	2372		c. 1-(5-fluoropentyl)-3-(2,2,3,3-
2427	2373		tetramethylcyclopropoyl)indole (XLR11);
2428	2374		9. Indole Amides: Any compound containing a 1H -Indole-3-
2429	2375		carboxamide structure with or without substitution at the nitrogen
2430	2376		atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
2431	2377		cycloalkylmethyl, cycloalkylethyl, benzy l, halobenzyl, 1-(N-methyl-
2432	2378		2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
2433	2379		pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
2434	2380		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
2435	2381		halophenyl group, whether or not substituted at the ca rboxamide
2436	2382		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
2437	2383		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
2438	2384		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
2439	2385		dimethyl-1-oxobutan-2-yl or pyrrole group, and whet her or not
2440	2386		further substituted in the indole, adamantyl, naphthyl, phenyl,
2441	2387		pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole
2442	2388		Amides include, but are not limited to:
2443	2389		a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide
2444	2390		(2NE1),
2445	2391
2446		-	SB1338 HFLR Page 49
2447		-	BOLD FACE denotes Committee Amendments. 1
	2392	+	ENGR. S. B. NO. 1338 Page 49 1
2448	2393		2
2449	2394		3
2450	2395		4
2451	2396		5
2452	2397		6
2453	2398		7
2454	2399		8
2455	2400		9
2456	2401		10
2457	2402		11
2458	2403		12
2459	2404		13
2460	2405		14
2461	2406		15
2462	2407		16
2463	2408		17
2464	2409		18
2465	2410		19
2466	2411		20
2467	2412		21
2468	2413		22
2469	2414		23
2470	2415		24
2471	2416
2472	2417		b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-
2473	2418		carboxamide (STS-135),
2474	2419		c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
2475	2420		indole-3-carboxamide (ADBICA),
2476	2421		d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
2477	2422		fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
2478	2423		e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide
2479	2424		(NNE1),
2480	2425		f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
2481	2426		carboxamide (5F-NNE1),
2482	2427		g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
2483	2428		or
2484	2429		h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide
2485	2430		(5F-SDB-006);
2486	2431		10. Indole Esters: Any compound containing a 1H -Indole-3-
2487	2432		carboxylate structure with or without substitution at the nitrogen
2488	2433		atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
2489	2434		cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
2490	2435		2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-2-
2491	2436		pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
2492	2437		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, pheny l, or
2493	2438		halophenyl group, whether or not substituted at the carboxylate
2494	2439		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
2495	2440		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
2496	2441
2497		-	SB1338 HFLR Page 50
2498		-	BOLD FACE denotes Committee Amendments. 1
	2442	+	ENGR. S. B. NO. 1338 Page 50 1
2499	2443		2
2500	2444		3
2501	2445		4
2502	2446		5
2503	2447		6
2504	2448		7
2505	2449		8
2506	2450		9
2507	2451		10
2508	2452		11
2509	2453		12
2510	2454		13
2511	2455		14
2512	2456		15
2513	2457		16
2514	2458		17
2515	2459		18
2516	2460		19
2517	2461		20
2518	2462		21
2519	2463		22
2520	2464		23
2521	2465		24
2522	2466
2523	2467		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
2524	2468		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
2525	2469		further substituted in the indole, adamantyl, naphthyl, phenyl,
2526	2470		pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole
2527	2471		Esters include, but are not limited to:
2528	2472		a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
2529	2473		22),
2530	2474		b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
2531	2475		carboxylate (5F-PB-22),
2532	2476		c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
2533	2477		carboxylate (BB-22),
2534	2478		d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
2535	2479		carboxylate (FDU-PB-22), or
2536	2480		e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
2537	2481		carboxylate (NM2201);
2538	2482		11. Adamantanoylindoles: Any compound containing an
2539	2483		adamantanyl-(1H-indol-3-yl)methanone structure with or without
2540	2484		substitution at the nitrogen at om of the indole ring by an a lkyl,
2541	2485		haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
2542	2486		benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
2543	2487		morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
2544	2488		morpholinyl)methyl, (tetra hydropyran-4-yl)methyl, 1-methylazepanyl,
2545	2489		phenyl, or halophenyl group, whether or not further substituted in
2546	2490		the indole ring to any extent and whether or not substituted in the
2547	2491
2548		-	SB1338 HFLR Page 51
2549		-	BOLD FACE denotes Committee Amendments. 1
	2492	+	ENGR. S. B. NO. 1338 Page 51 1
2550	2493		2
2551	2494		3
2552	2495		4
2553	2496		5
2554	2497		6
2555	2498		7
2556	2499		8
2557	2500		9
2558	2501		10
2559	2502		11
2560	2503		12
2561	2504		13
2562	2505		14
2563	2506		15
2564	2507		16
2565	2508		17
2566	2509		18
2567	2510		19
2568	2511		20
2569	2512		21
2570	2513		22
2571	2514		23
2572	2515		24
2573	2516
2574	2517		adamantyl ring to any extent. Adamantanoylindoles include, but are
2575	2518		not limited to:
2576	2519		a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
2577	2520		indol-3-yl]methanone (AM1248), or
2578	2521		b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
2579	2522		001);
2580	2523		12. Carbazole Ketone: Any compound containing (9H -carbazole-3-
2581	2524		yl) methanone structure with or wit hout substitution at the nitr ogen
2582	2525		atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl,
2583	2526		alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
2584	2527		(N-methyl-2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-
2585	2528		2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
2586	2529		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
2587	2530		halophenyl group, with substitution at the carbon of the methanone
2588	2531		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
2589	2532		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
2590	2533		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
2591	2534		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
2592	2535		further substituted at the carbazole, adamantyl, naphthyl, phenyl,
2593	2536		pyrrole, quinolinyl, or cycloa lkyl rings to any extent. Ca rbazole
2594	2537		Ketones include, but are not limited to, naphthalen -1-yl(9-pentyl-
2595	2538		9H-carbazol-3-yl)methanone (EG-018);
2596	2539		13. Benzimidazole Ketone: Any compound containing
2597	2540		(benzimidazole-2-yl) methanone structure with or without
2598	2541
2599		-	SB1338 HFLR Page 52
2600		-	BOLD FACE denotes Committee Amendments. 1
	2542	+	ENGR. S. B. NO. 1338 Page 52 1
2601	2543		2
2602	2544		3
2603	2545		4
2604	2546		5
2605	2547		6
2606	2548		7
2607	2549		8
2608	2550		9
2609	2551		10
2610	2552		11
2611	2553		12
2612	2554		13
2613	2555		14
2614	2556		15
2615	2557		16
2616	2558		17
2617	2559		18
2618	2560		19
2619	2561		20
2620	2562		21
2621	2563		22
2622	2564		23
2623	2565		24
2624	2566
2625	2567		substitution at either nitrogen atom of the benzimidazole ring by an
2626	2568		alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalky lmethyl,
2627	2569		cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-2-
2628	2570		piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
2629	2571		pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
2630	2572		(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
2631	2573		halophenyl group, with s ubstitution at the carbon of the methanone
2632	2574		group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
2633	2575		cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
2634	2576		1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
2635	2577		dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
2636	2578		further substituted in the benzimidazole, adamantyl, naphthyl,
2637	2579		phenyl, pyrrole, quinolinyl, or cycloal kyl rings to any extent.
2638	2580		Benzimidazole Ketones include, but are not limited to:
2639	2581		a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
2640	2582		l)methanone (JWH-018 benzimidazole analog), or
2641	2583		b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
2642	2584		yl)(naphthalen-1-yl)methanone (FUBIMINA); and
2643	2585		14. Modified by Replacement: any compound defined in this
2644	2586		subsection that is modified by replac ement of a carbon with nitrogen
2645	2587		in the indole, naphthyl, indene, benzimidazole, or carbazole ring.
2646	2588		H. Any prescription drug approved by the feder al Food and Drug
2647	2589		Administration under the provisions of Section 505 of the Federal
2648	2590		Food, Drug and Cosmetic Act , Title 21 of the United States Code,
2649	2591
2650		-	SB1338 HFLR Page 53
2651		-	BOLD FACE denotes Committee Amendments. 1
	2592	+	ENGR. S. B. NO. 1338 Page 53 1
2652	2593		2
2653	2594		3
2654	2595		4
2655	2596		5
2656	2597		6
2657	2598		7
2658	2599		8
2659	2600		9
2660	2601		10
2661	2602		11
2662	2603		12
2663	2604		13
2664	2605		14
2665	2606		15
2666	2607		16
2667	2608		17
2668	2609		18
2669	2610		19
2670	2611		20
2671	2612		21
2672	2613		22
2673	2614		23
2674	2615		24
2675	2616
2676	2617		Section 355, that is designated, rescheduled or deleted as a
2677	2618		controlled substance under federal law by the U nited States Drug
2678	2619		Enforcement Administration shall be excluded from Schedule I and
2679	2620		shall be prescribed, distri buted, dispensed or used in accordance
2680	2621		with federal law upon the issuance of a notice, final rule or
2681	2622		interim final rule by the United States Drug Enforcement
2682	2623		Administration designating, rescheduling or deleting as a controlled
2683	2624		substance such a drug product under federal law, unless and until
2684	2625		the Board of Pharmacy takes action pursuant to Section 2 -201 of this
2685	2626		title. If the Board of Pharmacy does no t take action pursuant to
2686	2627		Section 2-201 of this title, the drug product shall be deemed to be
2687	2628		designated, rescheduled or deleted as a controlled substance in
2688	2629		accordance with federal law and in compliance with the Uniform
2689	2630		Controlled Dangerous Substances Act .
2690	2631		SECTION 3. AMENDATORY 63 O.S. 2021, Section 2 -208, is
2691	2632		amended to read as follows:
2692	2633		Section 2-208. The controlled substances listed in this section
2693	2634		are included in Schedule III.
2694	2635		A. Unless listed in another schedule, any material, compound,
2695	2636		mixture, or preparation, which contains any quantity of the
2696	2637		following substances or any other subs tance having a potential for
2697	2638		abuse associated with a stimulant or depressant effect on the
2698	2639		central nervous system:
2699	2640
2700		-	SB1338 HFLR Page 54
2701		-	BOLD FACE denotes Committee Amendments. 1
	2641	+	ENGR. S. B. NO. 1338 Page 54 1
2702	2642		2
2703	2643		3
2704	2644		4
2705	2645		5
2706	2646		6
2707	2647		7
2708	2648		8
2709	2649		9
2710	2650		10
2711	2651		11
2712	2652		12
2713	2653		13
2714	2654		14
2715	2655		15
2716	2656		16
2717	2657		17
2718	2658		18
2719	2659		19
2720	2660		20
2721	2661		21
2722	2662		22
2723	2663		23
2724	2664		24
2725	2665
2726	2666		1. Any drug product containing gamma -hydroxybutyric acid,
2727	2667		including its salts, isomers, and salts of isomers, for which an
2728	2668		application has been approved under Section 505 of the Federal Food,
2729	2669		Drug, and Cosmetic Act;
2730	2670		2. Any material, compound, mixture, or preparation which
2731	2671		contains any quantity of the following ho rmonal substances or
2732	2672		steroids, including their salts, isomers, esters and salts o f
2733	2673		isomers and esters, when the existence of these salts, isomers,
2734	2674		esters, and salts of isomers and esters is possible within the
2735	2675		specific chemical designation:
2736	2676		a. Boldenone,
2737	2677		b. Chlorotestosterone,
2738	2678		c. Clostebol,
2739	2679		d. Dehydrochlormethyltestosterone,
2740	2680		e. Dihydrotestosterone,
2741	2681		f. Drostanolone,
2742	2682		g. Ethylestrenol,
2743	2683		h. Fluoxymesterone,
2744	2684		i. Formebolone,
2745	2685		j. Mesterolone,
2746	2686		k. Methandienone,
2747	2687		l. Methandranone,
2748	2688		m. Methandriol,
2749	2689		n. Methandrostenolone,
2750	2690
2751		-	SB1338 HFLR Page 55
2752		-	BOLD FACE denotes Committee Amendments. 1
	2691	+	ENGR. S. B. NO. 1338 Page 55 1
2753	2692		2
2754	2693		3
2755	2694		4
2756	2695		5
2757	2696		6
2758	2697		7
2759	2698		8
2760	2699		9
2761	2700		10
2762	2701		11
2763	2702		12
2764	2703		13
2765	2704		14
2766	2705		15
2767	2706		16
2768	2707		17
2769	2708		18
2770	2709		19
2771	2710		20
2772	2711		21
2773	2712		22
2774	2713		23
2775	2714		24
2776	2715
2777	2716		o. Methenolone,
2778	2717		p. Methyltestosterone, except as provided in subsection E
2779	2718		of this section,
2780	2719		q. Mibolerone,
2781	2720		r. Nandrolone,
2782	2721		s. Norethandrolone,
2783	2722		t. Oxandrolone,
2784	2723		u. Oxymesterone,
2785	2724		v. Oxymetholone,
2786	2725		w. Stanolone,
2787	2726		x. Stanozolol,
2788	2727		y. Testolactone,
2789	2728		z. Testosterone, except as provided in subsection E of
2790	2729		this section, and
2791	2730		aa. Trenbolone;
2792	2731		3. Any substance which contains any quantity of a derivative of
2793	2732		barbituric acid, or any salt of a derivative of barbituric acid;
2794	2733		4. Benzephetamine and its salts;
2795	2734		5. Buprenorphine;
2796	2735		6. Butalbital/acetaminophen/caffeine;
2797	2736		7. Chlorhexadol;
2798	2737		8. Chlorphentermine and i ts salts;
2799	2738		9. Clortermine;
2800	2739		10. Glutethimide;
2801	2740
2802		-	SB1338 HFLR Page 56
2803		-	BOLD FACE denotes Committee Amendments. 1
	2741	+	ENGR. S. B. NO. 1338 Page 56 1
2804	2742		2
2805	2743		3
2806	2744		4
2807	2745		5
2808	2746		6
2809	2747		7
2810	2748		8
2811	2749		9
2812	2750		10
2813	2751		11
2814	2752		12
2815	2753		13
2816	2754		14
2817	2755		15
2818	2756		16
2819	2757		17
2820	2758		18
2821	2759		19
2822	2760		20
2823	2761		21
2824	2762		22
2825	2763		23
2826	2764		24
2827	2765
2828	2766		11. Ketamine, its salts, isomers, and salts of isomers;
2829	2767		12. Lysergic acid;
2830	2768		13. Lysergic acid amide;
2831	2769		14. Mazindol;
2832	2770		15. Methyprylon;
2833	2771		16. Phendimetrazine;
2834	2772		17. Phenylacetone (P2P);
2835	2773		18. Sulfondiethylmethane;
2836	2774		19. Sulfonethylmethane;
2837	2775		20. Sulfonmethane;
2838	2776		21. Tetrahydrocannibinols Delta-9 tetrahydrocannabinol ;
2839	2777		22. 1-Phenycyclohexylamine; or
2840	2778		23. 1-Piperidinocychexanecarbo nitrile (PCC).
2841	2779		Livestock implants as regulated by the Federal Food and Drug
2842	2780		Administration shall be exempt.
2843	2781		B. Nalorphine.
2844	2782		C. Unless listed in another schedule, any material, compound,
2845	2783		mixture, or preparation containing limited quantities of any of the
2846	2784		following narcotic drugs, or any salts thereof:
2847	2785		1. Not more than on e and eight-tenths (1.8) grams of codeine or
2848	2786		any of its salts, per one hundred (100) milliliters or not more than
2849	2787		ninety (90) milligrams per dosage unit, with an equal or greater
2850	2788		quantity of an isoquinoline alkaloid of opium;
2851	2789
2852		-	SB1338 HFLR Page 57
2853		-	BOLD FACE denotes Committee Amendments. 1
	2790	+	ENGR. S. B. NO. 1338 Page 57 1
2854	2791		2
2855	2792		3
2856	2793		4
2857	2794		5
2858	2795		6
2859	2796		7
2860	2797		8
2861	2798		9
2862	2799		10
2863	2800		11
2864	2801		12
2865	2802		13
2866	2803		14
2867	2804		15
2868	2805		16
2869	2806		17
2870	2807		18
2871	2808		19
2872	2809		20
2873	2810		21
2874	2811		22
2875	2812		23
2876	2813		24
2877	2814
2878	2815		2. Not more than one and eigh t-tenths (1.8) grams o f codeine or
2879	2816		any of its salts, per one hundred (100) milliliters or not more than
2880	2817		ninety (90) milligrams per dosage unit, with one or more active,
2881	2818		nonnarcotic ingredients in r ecognized therapeutic amounts;
2882	2819		3. Not more than one and ei ght-tenths (1.8) grams of
2883	2820		dihydrocodeine or any of its salts, per one hundred (100)
2884	2821		milliliters or not more than ninety (90) milligrams per dosage unit,
2885	2822		with one or more active, nonnarcotic ingredi ents in recognized
2886	2823		therapeutic amounts;
2887	2824		4. Not more than three hundred (300) mil ligrams of
2888	2825		ethylmorphine or any of its salts, per one hundred (100) milliliters
2889	2826		or not more than fifteen (15) milligrams per dosage unit, with one
2890	2827		or more ingredients in recog nized therapeutic amounts;
2891	2828		5. Not more than five hundred ( 500) milligrams of opi um per one
2892	2829		hundred (100) milliliters or per one hundred (100) grams, or not
2893	2830		more than twenty-five (25) milligrams per dosage unit, with one or
2894	2831		more active, nonnarcotic ingredi ents in recognized therapeutic
2895	2832		amounts; or
2896	2833		6. Not more than fifty (50) milligram s of morphine or any of
2897	2834		its salts, per one hundred (100) milliliters or per one hundred
2898	2835		(100) grams with one or more active, nonnarcotic ingredients in
2899	2836		recognized therapeutic amounts.
2900	2837		D. The Board of Pharmacy may except by rule any c ompound,
2901	2838		mixture, or preparation containing any stimulant or depressant
2902	2839
2903		-	SB1338 HFLR Page 58
2904		-	BOLD FACE denotes Committee Amendments. 1
	2840	+	ENGR. S. B. NO. 1338 Page 58 1
2905	2841		2
2906	2842		3
2907	2843		4
2908	2844		5
2909	2845		6
2910	2846		7
2911	2847		8
2912	2848		9
2913	2849		10
2914	2850		11
2915	2851		12
2916	2852		13
2917	2853		14
2918	2854		15
2919	2855		16
2920	2856		17
2921	2857		18
2922	2858		19
2923	2859		20
2924	2860		21
2925	2861		22
2926	2862		23
2927	2863		24
2928	2864
2929	2865		substance listed in subsections A and B of this section from the
2930	2866		application of all or any part of the Uniform Controlled Dan gerous
2931	2867		Substances Act if the compound, mixture, or preparat ion contains one
2932	2868		or more active medicinal ingredients not having a stimulant or
2933	2869		depressant effect on the central nervous system, and if the
2934	2870		admixtures are included therein in combinations, quantity ,
2935	2871		proportion, or concentration that vitiate the potential f or abuse of
2936	2872		the substances which have a stimulant or depressant effect on the
2937	2873		central nervous system.
2938	2874		E. The following hormonal substances or steroids are exempt
2939	2875		from classification as Schedule II I controlled dangerous substances:
2940	2876		1. Estratest, containing 1.25 mg esterified e strogens and 2.5
2941	2877		mg methyltestosterone;
2942	2878		2. Estratest HS, containing 0.625 mg es terified estrogens and
2943	2879		1.25 mg methyltestosterone;
2944	2880		3. Premarin with Methyltestosterone, contai ning 1.25 mg
2945	2881		conjugated estrogens and 10.0 mg methyltestosterone;
2946	2882		4. Premarin with Methyltestosterone, containing 0.625 mg
2947	2883		conjugated estrogens and 5.0 mg methy ltestosterone;
2948	2884		5. Testosterone Cypionate - Estrodiol Cypionate injection,
2949	2885		containing 50 mg/ml Testosterone Cypionate; and
2950	2886		6. Testosterone Enanthate - Estradiol Valerate injec tion,
2951	2887		containing 90 mg/ml Testosterone Enanthate and 4 mg/ml Estradiol
2952	2888		Valerate.
2953	2889
2954		-	SB1338 HFLR Page 59
2955		-	BOLD FACE denotes Committee Amendments. 1
	2890	+	ENGR. S. B. NO. 1338 Page 59 1
2956	2891		2
2957	2892		3
2958	2893		4
2959	2894		5
2960	2895		6
2961	2896		7
2962	2897		8
2963	2898		9
2964	2899		10
2965	2900		11
2966	2901		12
2967	2902		13
2968	2903		14
2969	2904		15
2970	2905		16
2971	2906		17
2972	2907		18
2973	2908		19
2974	2909		20
2975	2910		21
2976	2911		22
2977	2912		23
2978	2913		24
2979	2914
2980	2915		SECTION 4. AMENDATORY 63 O.S. 2021, Section 427.2, as
2981	2916		last amended by Section 4, Chapter 584, O.S.L. 2021, is amended to
2982	2917		read as follows:
2983	2918		Section 427.2. As used in the Oklahoma Medical Marijuana and
2984	2919		Patient Protection Act:
2985	2920		1. “Advertising” means the act of providing consideration for
2986	2921		the publication, dissemination, solic itation or circulation, of
2987	2922		visual, oral or written communication to induce direct ly or
2988	2923		indirectly any person to patronize a particular medical marijuana
2989	2924		business, or to purchase particular medical marijuana or a medical
2990	2925		marijuana product. Advertising incl udes marketing, but does not
2991	2926		include packaging and labeling;
2992	2927		2. “Authority” means the Oklahoma Medical Marijuana Authority;
2993	2928		3. “Batch number” means a unique numeric or alphanumeric
2994	2929		identifier assigned prior to testing to allow for inventory tracking
2995	2930		and traceability;
2996	2931		4. “Cannabinoid” means any of the chemical compounds that are
2997	2932		active principles of marijuana;
2998	2933		5. “Caregiver” means a family member or assistant who regularly
2999	2934		looks after a medical marijuana license holder whom a physician
3000	2935		attests needs assistance;
3001	2936		6. “Child-resistant” means special packaging that is:
3002	2937		a. designed or constructed to be significantly difficult
3003	2938		for children under five (5) years of age to open and
3004	2939
3005		-	SB1338 HFLR Page 60
3006		-	BOLD FACE denotes Committee Amendments. 1
	2940	+	ENGR. S. B. NO. 1338 Page 60 1
3007	2941		2
3008	2942		3
3009	2943		4
3010	2944		5
3011	2945		6
3012	2946		7
3013	2947		8
3014	2948		9
3015	2949		10
3016	2950		11
3017	2951		12
3018	2952		13
3019	2953		14
3020	2954		15
3021	2955		16
3022	2956		17
3023	2957		18
3024	2958		19
3025	2959		20
3026	2960		21
3027	2961		22
3028	2962		23
3029	2963		24
3030	2964
3031	2965		not difficult for normal adults to use properly as
3032	2966		defined by 16 C.F.R. 1700.15 (19 95) and 16 C.F.R.
3033	2967		1700.20 (1995),
3034	2968		b. opaque so that the outermost packaging does not allow
3035	2969		the product to be seen without opening the packaging
3036	2970		material, and
3037	2971		c. resealable to maintain its child -resistant
3038	2972		effectiveness for multiple openings for any product
3039	2973		intended for more than a single use or containing
3040	2974		multiple servings;
3041	2975		7. “Clone” means a nonflowering plant cut from a mother plant
3042	2976		that is capable of developing into a new plant and has shown no
3043	2977		signs of flowering;
3044	2978		8. “Commissioner” means the State Commi ssioner of Health;
3045	2979		9. “Complete application ” means a document pre pared in
3046	2980		accordance with the provisions set forth in the Oklahoma Medical
3047	2981		Marijuana and Patient Protection Act, rules promulgated pursuant
3048	2982		thereto, and the forms and instructions provided by the Department
3049	2983		including any supporting documentation required an d the applicable
3050	2984		license application fee;
3051	2985		10. “Department” means the State Department of Health;
3052	2986		11. “Director” means the Executive Director of the Oklahoma
3053	2987		Medical Marijuana Authority;
3054	2988
3055		-	SB1338 HFLR Page 61
3056		-	BOLD FACE denotes Committee Amendments. 1
	2989	+	ENGR. S. B. NO. 1338 Page 61 1
3057	2990		2
3058	2991		3
3059	2992		4
3060	2993		5
3061	2994		6
3062	2995		7
3063	2996		8
3064	2997		9
3065	2998		10
3066	2999		11
3067	3000		12
3068	3001		13
3069	3002		14
3070	3003		15
3071	3004		16
3072	3005		17
3073	3006		18
3074	3007		19
3075	3008		20
3076	3009		21
3077	3010		22
3078	3011		23
3079	3012		24
3080	3013
3081	3014		12. “Dispense” means the selling of medical marijuana or a
3082	3015		medical marijuana product to a qualified patient or the designated
3083	3016		caregiver of the patient that is packaged in a suitable container
3084	3017		appropriately labeled for subsequent administration to or use by a
3085	3018		qualifying patient;
3086	3019		13. “Dispensary” means a medical marijuana dispensary, an
3087	3020		entity that has been licensed by the Department pursuant to the
3088	3021		Oklahoma Medical Marijuana and Patient Protection Act to purchase
3089	3022		medical marijuana or medical marijuana produc ts from a licensed
3090	3023		medical marijuana commercial grower or medical marijuana processor,
3091	3024		sell medical marijuana or medical marijuana products to patients and
3092	3025		caregivers as defined under the Oklahoma Medical Marijuana and
3093	3026		Patient Protection Act, or sell or tr ansfer products to another
3094	3027		dispensary;
3095	3028		14. “Edible medical mariju ana product” means any medical-
3096	3029		marijuana-infused product for which the intended use is oral
3097	3030		consumption including, but not limited to, any type of food, drink
3098	3031		or pill;
3099	3032		15. “Entity” means an individual, general partnership, limited
3100	3033		partnership, limited lia bility company, trust, estate, association,
3101	3034		corporation, cooperative or any other legal or commercial entity;
3102	3035		16. “Flower” means the reproductive organs of the marijuana or
3103	3036		cannabis plant referred to as the bud or parts of the plant that are
3104	3037
3105		-	SB1338 HFLR Page 62
3106		-	BOLD FACE denotes Committee Amendments. 1
	3038	+	ENGR. S. B. NO. 1338 Page 62 1
3107	3039		2
3108	3040		3
3109	3041		4
3110	3042		5
3111	3043		6
3112	3044		7
3113	3045		8
3114	3046		9
3115	3047		10
3116	3048		11
3117	3049		12
3118	3050		13
3119	3051		14
3120	3052		15
3121	3053		16
3122	3054		17
3123	3055		18
3124	3056		19
3125	3057		20
3126	3058		21
3127	3059		22
3128	3060		23
3129	3061		24
3130	3062
3131	3063		harvested and used to consume in a variety of medical marijuana
3132	3064		products;
3133	3065		17. “Flowering” means the reproductive state of the marijuana
3134	3066		or cannabis plant in which there are physical signs of flower or
3135	3067		budding out of the nodes of the stem;
3136	3068		18. “Food-based medical marijuana concentrate” means a medical
3137	3069		marijuana concentrate that was produced by extracting cannabinoids
3138	3070		from medical marijuana through the use of propylene glycol,
3139	3071		glycerin, butter, olive oil, coconut oil or other typical food-safe
3140	3072		cooking fats;
3141	3073		19. “Good cause” for purposes of an initial, renewal or
3142	3074		reinstatement license application, or for purposes of discipline of
3143	3075		a licensee, means:
3144	3076		a. the licensee or applicant has violated, does not meet,
3145	3077		or has failed to comply with any of the terms,
3146	3078		conditions or provisions of the act, any rules
3147	3079		promulgated pursuant thereto, or any supplemental
3148	3080		relevant state or local law, rule or regulation,
3149	3081		b. the licensee or applicant has failed to comply with
3150	3082		any special terms or conditions that were placed upon
3151	3083		the license pursuant to an order of the State
3152	3084		Department of Health, Oklahoma Medical Marijuana
3153	3085		Authority or the municipality, or
3154	3086
3155		-	SB1338 HFLR Page 63
3156		-	BOLD FACE denotes Committee Amendments. 1
	3087	+	ENGR. S. B. NO. 1338 Page 63 1
3157	3088		2
3158	3089		3
3159	3090		4
3160	3091		5
3161	3092		6
3162	3093		7
3163	3094		8
3164	3095		9
3165	3096		10
3166	3097		11
3167	3098		12
3168	3099		13
3169	3100		14
3170	3101		15
3171	3102		16
3172	3103		17
3173	3104		18
3174	3105		19
3175	3106		20
3176	3107		21
3177	3108		22
3178	3109		23
3179	3110		24
3180	3111
3181	3112		c. the licensed premises of a medical marijuana business
3182	3113		or applicant have been o perated in a manner that
3183	3114		adversely affects the public health or we lfare or the
3184	3115		safety of the immediate vicinity in which the
3185	3116		establishment is located;
3186	3117		20. “Harvest batch” means a specifically identified quantity of
3187	3118		medical marijuana that is uniform in str ain, cultivated utilizing
3188	3119		the same cultivation practices, harveste d at the same time from the
3189	3120		same location and cured under uniform conditions;
3190	3121		21. “Harvested marijuana” means post-flowering medical
3191	3122		marijuana not including trim, concentrate or waste;
3192	3123		22. “Heat- or pressure-based medical marijuana concentrate ”
3193	3124		means a medical marijuana concentrate that was produced by
3194	3125		extracting cannabinoids from medical marijuana through the use of
3195	3126		heat or pressure;
3196	3127		23. “Immature plant” means a nonflowering marijuana pla nt that
3197	3128		has not demonstrated signs of flowering;
3198	3129		24. “Inventory tracking system” means the required tracking
3199	3130		system that accounts for medical marijuana from either the seed or
3200	3131		immature plant stage until the medical marijuana or medical
3201	3132		marijuana product is sold to a patient at a medical marijuana
3202	3133		dispensary, transferred to a medical marijuana research facility,
3203	3134		destroyed by a medical marijuana business or used in a research
3204	3135		project by a medical marijuana research facility;
3205	3136
3206		-	SB1338 HFLR Page 64
3207		-	BOLD FACE denotes Committee Amendments. 1
	3137	+	ENGR. S. B. NO. 1338 Page 64 1
3208	3138		2
3209	3139		3
3210	3140		4
3211	3141		5
3212	3142		6
3213	3143		7
3214	3144		8
3215	3145		9
3216	3146		10
3217	3147		11
3218	3148		12
3219	3149		13
3220	3150		14
3221	3151		15
3222	3152		16
3223	3153		17
3224	3154		18
3225	3155		19
3226	3156		20
3227	3157		21
3228	3158		22
3229	3159		23
3230	3160		24
3231	3161
3232	3162		25. “Licensed patient” or “patient” means a person who has been
3233	3163		issued a medical marijuana patient license by the State Department
3234	3164		of Health or Oklahoma Medical Marijuana Authority;
3235	3165		26. “Licensed premises” means the premises specified in an
3236	3166		application for a medical marijuana business l icense, medical
3237	3167		marijuana research facility licen se or medical marijuana educatio n
3238	3168		facility license pursuant to the Oklahoma Medical Marijuana and
3239	3169		Patient Protection Act that are owned or in possession of the
3240	3170		licensee and within which the licensee is autho rized to cultivate,
3241	3171		manufacture, distribute, sell , store, transport, test or rese arch
3242	3172		medical marijuana or medical marijuana products in accordance with
3243	3173		the provisions of the Oklahoma Medical Marijuana and Patient
3244	3174		Protection Act and rules promulgated pursu ant thereto;
3245	3175		27. “Manufacture” means the production, propagation,
3246	3176		compounding or processing of a medical marijuana product, excluding
3247	3177		marijuana plants, either directly or indirectly by extraction from
3248	3178		substances of natural or synthetic origin, or independ ently by means
3249	3179		of chemical synthesis, or by a com bination of extraction and
3250	3180		chemical synthesis;
3251	3181		28. “Marijuana” shall have the same meaning as such term is
3252	3182		defined in Section 2 -101 of this title and shall not include any
3253	3183		plant or material containing delta -8 or delta-10
3254	3184		tetrahydrocannabinol which is grow n, processed or sold pursuant to
3255	3185		the provisions of the Oklahoma Industrial Hemp Program ;
3256	3186
3257		-	SB1338 HFLR Page 65
3258		-	BOLD FACE denotes Committee Amendments. 1
	3187	+	ENGR. S. B. NO. 1338 Page 65 1
3259	3188		2
3260	3189		3
3261	3190		4
3262	3191		5
3263	3192		6
3264	3193		7
3265	3194		8
3266	3195		9
3267	3196		10
3268	3197		11
3269	3198		12
3270	3199		13
3271	3200		14
3272	3201		15
3273	3202		16
3274	3203		17
3275	3204		18
3276	3205		19
3277	3206		20
3278	3207		21
3279	3208		22
3280	3209		23
3281	3210		24
3282	3211
3283	3212		29. “Material change” means any change that would require a
3284	3213		substantive revision to the standard operating procedures of a
3285	3214		licensee for the cultivation or production of medical marijuana,
3286	3215		medical marijuana concentrate or medical marijuana products;
3287	3216		30. “Mature plant” means a harvestable female marijuana plant
3288	3217		that is flowering;
3289	3218		31. “Medical marijuana business (MMB) ” means a licensed medical
3290	3219		marijuana dispensary, medi cal marijuana processor, medical marijuana
3291	3220		commercial grower, medical marijuana laboratory, medical marijuana
3292	3221		business operator or a medical marijuana transporter;
3293	3222		32. “Medical marijuana concentrate ” or “concentrate” means a
3294	3223		specific subset of medical mar ijuana that was produced by extr acting
3295	3224		cannabinoids from medical marijuana. Categories of medical
3296	3225		marijuana concentrate include water -based medical marijuana
3297	3226		concentrate, food-based medical marijuana concen trate, solvent-based
3298	3227		medical marijuana concentrat e, and heat- or pressure-based medical
3299	3228		marijuana concentrate;
3300	3229		33. “Medical marijuana commercial grower ” or “commercial
3301	3230		grower” means an entity licensed to cultivate, prepare and package
3302	3231		medical marijuana an d transfer or contract for transfer medical
3303	3232		marijuana to a medical marijuana disp ensary, medical marijuana
3304	3233		processor, any other medical marijuana commercial grower, medical
3305	3234		marijuana research facility, medical marijuana education facility
3306	3235		and pesticide manufacturers. A commercial grower may sell seeds,
3307	3236
3308		-	SB1338 HFLR Page 66
3309		-	BOLD FACE denotes Committee Amendments. 1
	3237	+	ENGR. S. B. NO. 1338 Page 66 1
3310	3238		2
3311	3239		3
3312	3240		4
3313	3241		5
3314	3242		6
3315	3243		7
3316	3244		8
3317	3245		9
3318	3246		10
3319	3247		11
3320	3248		12
3321	3249		13
3322	3250		14
3323	3251		15
3324	3252		16
3325	3253		17
3326	3254		18
3327	3255		19
3328	3256		20
3329	3257		21
3330	3258		22
3331	3259		23
3332	3260		24
3333	3261
3334	3262		flower or clones to commercial g rowers pursuant to the Oklahoma
3335	3263		Medical Marijuana and Patient Protection Act;
3336	3264		34. “Medical marijuana education facility ” or “education
3337	3265		facility” means a person or entity appr oved pursuant to the Oklahoma
3338	3266		Medical Marijuana and Patient Protection Act to ope rate a facility
3339	3267		providing training and education to individuals involving the
3340	3268		cultivation, growing, harvesting, curing, preparing, packaging or
3341	3269		testing of medical marijuana, o r the production, manufacture,
3342	3270		extraction, processing, packaging or creation of m edical-marijuana-
3343	3271		infused products or medical marijuana products as described in the
3344	3272		Oklahoma Medical Marijuana and Patient Protection Act;
3345	3273		35. “Medical-marijuana-infused product” means a product infused
3346	3274		with medical marijua na including, but not limited to , edible
3347	3275		products, ointments and tinctures;
3348	3276		36. “Medical marijuana product ” or “product” means a product
3349	3277		that contains cannabinoids that have been extracted from plant
3350	3278		material or the resin therefrom by physical or chemical means and is
3351	3279		intended for administration to a qualified patient including, but
3352	3280		not limited to, oils, tinctures, edibles, pills, topical forms,
3353	3281		gels, creams, vapors, patches, liquids and forms administered b y a
3354	3282		nebulizer, excluding live plant forms which a re considered medical
3355	3283		marijuana;
3356	3284		37. “Medical marijuana processor” means a person or entity
3357	3285		licensed pursuant to the Oklahoma Medical Marijuana and Patient
3358	3286
3359		-	SB1338 HFLR Page 67
3360		-	BOLD FACE denotes Committee Amendments. 1
	3287	+	ENGR. S. B. NO. 1338 Page 67 1
3361	3288		2
3362	3289		3
3363	3290		4
3364	3291		5
3365	3292		6
3366	3293		7
3367	3294		8
3368	3295		9
3369	3296		10
3370	3297		11
3371	3298		12
3372	3299		13
3373	3300		14
3374	3301		15
3375	3302		16
3376	3303		17
3377	3304		18
3378	3305		19
3379	3306		20
3380	3307		21
3381	3308		22
3382	3309		23
3383	3310		24
3384	3311
3385	3312		Protection Act to operate a business including the production,
3386	3313		manufacture, extraction, processing, packaging or creation of
3387	3314		concentrate, medical-marijuana-infused products or medical marijuana
3388	3315		products as described in the Oklahoma Medical Marijuana and Patient
3389	3316		Protection Act;
3390	3317		38. “Medical marijuana rese arch facility” or “research
3391	3318		facility” means a person or entity approved pursuant to the Oklahoma
3392	3319		Medical Marijuana and Patient Protection Act to conduct medical
3393	3320		marijuana research. A medical marijuana research facility is not a
3394	3321		medical marijuana business;
3395	3322		39. “Medical marijuana testing laboratory ” or “laboratory”
3396	3323		means a public or pr ivate laboratory licensed pursuant to the
3397	3324		Oklahoma Medical Marijuana and Patient Protection Act, to conduct
3398	3325		testing and research on medical marijuana and medical marijuana
3399	3326		products;
3400	3327		40. “Medical marijuana transporter ” or “transporter” means a
3401	3328		person or entity that is licensed pursuant to the Oklahoma Medical
3402	3329		Marijuana and Patient Protection Act. A medical marijuana
3403	3330		transporter does not include a medical marijuana business tha t
3404	3331		transports its own medical marijuana, medical m arijuana concentrate
3405	3332		or medical marijuana products to a property or facility adjacent to
3406	3333		or connected to the licensed premises if the property is another
3407	3334		licensed premises of the same medical marijuana busin ess;
3408	3335
3409		-	SB1338 HFLR Page 68
3410		-	BOLD FACE denotes Committee Amendments. 1
	3336	+	ENGR. S. B. NO. 1338 Page 68 1
3411	3337		2
3412	3338		3
3413	3339		4
3414	3340		5
3415	3341		6
3416	3342		7
3417	3343		8
3418	3344		9
3419	3345		10
3420	3346		11
3421	3347		12
3422	3348		13
3423	3349		14
3424	3350		15
3425	3351		16
3426	3352		17
3427	3353		18
3428	3354		19
3429	3355		20
3430	3356		21
3431	3357		22
3432	3358		23
3433	3359		24
3434	3360
3435	3361		41. “Medical marijuana waste” or “waste” means unused, surplus,
3436	3362		returned or out-of-date marijuana, plant debris of the plant of the
3437	3363		genus Cannabis including dead plants and all unused plant parts and
3438	3364		roots, except the term shall not include roots, st ems, stalks and
3439	3365		fan leaves;
3440	3366		42. “Medical use” means the acquisition, possession, use,
3441	3367		delivery, transfer or transportation of medical marijuana, medical
3442	3368		marijuana products, medical marijuana devices or paraphernalia
3443	3369		relating to the administration of medic al marijuana to treat a
3444	3370		licensed patient;
3445	3371		43. “Mother plant” means a marijuana plant that is grown or
3446	3372		maintained for the purpose of generating clones, and that will not
3447	3373		be used to produce plant material for sale to a medical marijuana
3448	3374		processor or medical marijuana dispensary;
3449	3375		44. “Oklahoma physician” or “physician” means a physician
3450	3376		licensed by and in good standing with the State Board of Medical
3451	3377		Licensure and Supervision, the State Board of Osteopathic Examiners
3452	3378		or the Board of Podiatric Medical Examine rs;
3453	3379		45. “Oklahoma resident” means an individual who can provide
3454	3380		proof of residency as required by the Oklahoma Medical Marijuana and
3455	3381		Patient Protection Act;
3456	3382		46. “Owner” means, except where the context otherwise requires,
3457	3383		a direct beneficial owner includi ng, but not limited to, all persons
3458	3384		or entities as follows:
3459	3385
3460		-	SB1338 HFLR Page 69
3461		-	BOLD FACE denotes Committee Amendments. 1
	3386	+	ENGR. S. B. NO. 1338 Page 69 1
3462	3387		2
3463	3388		3
3464	3389		4
3465	3390		5
3466	3391		6
3467	3392		7
3468	3393		8
3469	3394		9
3470	3395		10
3471	3396		11
3472	3397		12
3473	3398		13
3474	3399		14
3475	3400		15
3476	3401		16
3477	3402		17
3478	3403		18
3479	3404		19
3480	3405		20
3481	3406		21
3482	3407		22
3483	3408		23
3484	3409		24
3485	3410
3486	3411		a. all shareholders owning an interest of a corporate
3487	3412		entity and all officers of a corporate entity,
3488	3413		b. all partners of a general partnership,
3489	3414		c. all general partners and all limited partners that own
3490	3415		an interest in a limited partnership,
3491	3416		d. all members that own an interest in a limited
3492	3417		liability company,
3493	3418		e. all beneficiaries that hold a beneficial interest in a
3494	3419		trust and all trustees of a trust,
3495	3420		f. all persons or entities that own interest in a jo int
3496	3421		venture,
3497	3422		g. all persons or entities that o wn an interest in an
3498	3423		association,
3499	3424		h. the owners of any other type of legal entity, and
3500	3425		i. any other person holding an interest or convertible
3501	3426		note in any entity which owns, operates or manages a
3502	3427		licensed facility;
3503	3428		47. “Package” or “packaging” means any container or wrapper
3504	3429		that may be used by a medical marijuana business to enclose or
3505	3430		contain medical marijuana;
3506	3431		48. “Person” means a natural person, partnership, association,
3507	3432		business trust, company, corporation, estate, limited liability
3508	3433		company, trust or any other legal entity or organizati on, or a
3509	3434		manager, agent, owner, director, servant, officer or employee
3510	3435
3511		-	SB1338 HFLR Page 70
3512		-	BOLD FACE denotes Committee Amendments. 1
	3436	+	ENGR. S. B. NO. 1338 Page 70 1
3513	3437		2
3514	3438		3
3515	3439		4
3516	3440		5
3517	3441		6
3518	3442		7
3519	3443		8
3520	3444		9
3521	3445		10
3522	3446		11
3523	3447		12
3524	3448		13
3525	3449		14
3526	3450		15
3527	3451		16
3528	3452		17
3529	3453		18
3530	3454		19
3531	3455		20
3532	3456		21
3533	3457		22
3534	3458		23
3535	3459		24
3536	3460
3537	3461		thereof, except that “person” person does not include any
3538	3462		governmental organization;
3539	3463		49. “Pesticide” means any substance or mixture of substances
3540	3464		intended for preventing, destroying, r epelling or mitigating any
3541	3465		pest or any substance or mixture of substances intended for use as a
3542	3466		plant regulator, defoliant or desiccant, except that the term
3543	3467		“pesticide” pesticide shall not include any article that is a “new
3544	3468		animal drug” as designated by the United States Food and Drug
3545	3469		Administration;
3546	3470		50. “Production batch” means:
3547	3471		a. any amount of medical marijuana concentrate of the
3548	3472		same category and produced using the same e xtraction
3549	3473		methods, standard operating procedures and an
3550	3474		identical group of harves t batch of medical marijuana,
3551	3475		or
3552	3476		b. any amount of medical marijuana product of the same
3553	3477		exact type, produced using the same ingredients,
3554	3478		standard operating procedures and the same production
3555	3479		batch of medical marijuana concentrate;
3556	3480		51. “Public institution” means any entity established or
3557	3481		controlled by the federal government, state government, or a local
3558	3482		government or municipality including, but not limited to,
3559	3483		institutions of higher education or related research institutions;
3560	3484
3561		-	SB1338 HFLR Page 71
3562		-	BOLD FACE denotes Committee Amendments. 1
	3485	+	ENGR. S. B. NO. 1338 Page 71 1
3563	3486		2
3564	3487		3
3565	3488		4
3566	3489		5
3567	3490		6
3568	3491		7
3569	3492		8
3570	3493		9
3571	3494		10
3572	3495		11
3573	3496		12
3574	3497		13
3575	3498		14
3576	3499		15
3577	3500		16
3578	3501		17
3579	3502		18
3580	3503		19
3581	3504		20
3582	3505		21
3583	3506		22
3584	3507		23
3585	3508		24
3586	3509
3587	3510		52. “Public money” means any funds or money obtained by the
3588	3511		holder from any governmental entity including, but not limited to,
3589	3512		research grants;
3590	3513		53. “Recommendation” means a document that is signed or
3591	3514		electronically submitted by a physician on behalf of a patient for
3592	3515		the use of medical marijuana pursuant to the Oklahoma Medical
3593	3516		Marijuana and Patient Protection Act;
3594	3517		54. “Registered to conduct business ” means a person that has
3595	3518		provided proof that the busines s applicant is in good standing with
3596	3519		the Oklahoma Secretary of State and Oklahoma Tax Commission;
3597	3520		55. “Remediation” means the process by which the medical
3598	3521		marijuana flower or trim, which has failed microbial testing, is
3599	3522		processed into solvent -based medical marijuana concentrate and
3600	3523		retested as required by the Oklahoma Medical Marijuan a and Patient
3601	3524		Protection Act;
3602	3525		56. “Research project” means a discrete scientific endeavor to
3603	3526		answer a research question or a set of research questions related to
3604	3527		medical marijuana and is required for a medical marijuana research
3605	3528		license. A research proje ct shall include a description of a
3606	3529		defined protocol, clearly articulated goals, defined methods and
3607	3530		outputs, and a defined start and end date. The description shall
3608	3531		demonstrate that the research project will comply with all
3609	3532		requirements in the Oklahoma M edical Marijuana and Patient
3610	3533		Protection Act and rules promulgated pursuant thereto. All research
3611	3534
3612		-	SB1338 HFLR Page 72
3613		-	BOLD FACE denotes Committee Amendments. 1
	3535	+	ENGR. S. B. NO. 1338 Page 72 1
3614	3536		2
3615	3537		3
3616	3538		4
3617	3539		5
3618	3540		6
3619	3541		7
3620	3542		8
3621	3543		9
3622	3544		10
3623	3545		11
3624	3546		12
3625	3547		13
3626	3548		14
3627	3549		15
3628	3550		16
3629	3551		17
3630	3552		18
3631	3553		19
3632	3554		20
3633	3555		21
3634	3556		22
3635	3557		23
3636	3558		24
3637	3559
3638	3560		and development conducted by a medical marijuana research facility
3639	3561		shall be conducted in furtherance of an approved research project;
3640	3562		57. “Revocation” means the final decision by the Department
3641	3563		that any license issued pursuant to the Oklahoma Medical Marijuana
3642	3564		and Patient Protection Act is rescinded because the individual or
3643	3565		entity does not comply with the applicable requirements set forth in
3644	3566		the Oklahoma Medical Marijuana and Patient Protection Act or rules
3645	3567		promulgated pursuant thereto;
3646	3568		58. “School” means a public or private preschool or a public or
3647	3569		private elementary or secondar y school which is primarily used for
3648	3570		classroom instruction. A homeschool, daycar e or child-care facility
3649	3571		shall not be considered a “school” school as used in the Oklahoma
3650	3572		Medical Marijuana and Patient Protection Act;
3651	3573		59. “Shipping container” means a hard-sided container with a
3652	3574		lid or other enclosure that can be secured in place. A s hipping
3653	3575		container is used solely for the transport of medical marijuana,
3654	3576		medical marijuana concentrate, or medical marijuana products between
3655	3577		medical marijuana businesses, a m edical marijuana research facility,
3656	3578		or a medical marijuana education facility;
3657	3579		60. “Solvent-based medical marijuana concentrate ” means a
3658	3580		medical marijuana concentrate that was produced by extracting
3659	3581		cannabinoids from medical marijuana through the use of a solvent
3660	3582		approved by the Department;
3661	3583
3662		-	SB1338 HFLR Page 73
3663		-	BOLD FACE denotes Committee Amendments. 1
	3584	+	ENGR. S. B. NO. 1338 Page 73 1
3664	3585		2
3665	3586		3
3666	3587		4
3667	3588		5
3668	3589		6
3669	3590		7
3670	3591		8
3671	3592		9
3672	3593		10
3673	3594		11
3674	3595		12
3675	3596		13
3676	3597		14
3677	3598		15
3678	3599		16
3679	3600		17
3680	3601		18
3681	3602		19
3682	3603		20
3683	3604		21
3684	3605		22
3685	3606		23
3686	3607		24
3687	3608
3688	3609		61. “State Question” means Oklahoma State Q uestion No. 788,
3689	3610		Initiative Petition No. 412, approved by a majority vote of the
3690	3611		citizens of Oklahoma on June 26, 2018;
3691	3612		62. “Strain” means the classification of marijuana or cannabis
3692	3613		plants in either pure sativa, indica, afghanica, ruderalis or hybrid
3693	3614		varieties;
3694	3615		63. “THC” means delta-9 tetrahydrocannabinol, which is the
3695	3616		primary psychotropic cannabinoid in marijuana formed by
3696	3617		decarboxylation of naturally tetrahydrocannabinolic acid, which
3697	3618		generally occurs by exposure to heat . Any tetrahydrocannabinols as
3698	3619		such term is defined in Section 2-101 of this title other than
3699	3620		delta-9 tetrahydrocannabinol shall be subject to the provisions of
3700	3621		paragraph 94 of subsection C of Section 2 -204 of this title;
3701	3622		64. “Test batch” means with regard to usable marijuana, a
3702	3623		homogenous, identified quantity of usable marijuana by strain, no
3703	3624		greater than ten (10) pounds, that is harvested during a seven -day
3704	3625		period from a specified cultivation area, and wi th regard to oils,
3705	3626		vapors and waxes derived from usable marijuana, means an ident ified
3706	3627		quantity that is uniform, that is intended to meet specifications
3707	3628		for identity, strength and composition, and that is manufactured,
3708	3629		packaged and labeled during a specifi ed time period according to a
3709	3630		single manufacturing, packaging and labeling protoc ol;
3710	3631		65. “Transporter agent” means a person who transports medical
3711	3632		marijuana or medical marijuana products for a licensed transporter
3712	3633
3713		-	SB1338 HFLR Page 74
3714		-	BOLD FACE denotes Committee Amendments. 1
	3634	+	ENGR. S. B. NO. 1338 Page 74 1
3715	3635		2
3716	3636		3
3717	3637		4
3718	3638		5
3719	3639		6
3720	3640		7
3721	3641		8
3722	3642		9
3723	3643		10
3724	3644		11
3725	3645		12
3726	3646		13
3727	3647		14
3728	3648		15
3729	3649		16
3730	3650		17
3731	3651		18
3732	3652		19
3733	3653		20
3734	3654		21
3735	3655		22
3736	3656		23
3737	3657		24
3738	3658
3739	3659		and holds a transporter agent license pur suant to the Oklahoma
3740	3660		Medical Marijuana and Patient Protection Act;
3741	3661		66. “Universal symbol” means the image established by the State
3742	3662		Department of Health or Oklahoma Medical Marijuana Authority and
3743	3663		made available to licensees through its website indicating that the
3744	3664		medical marijuana or the medical marijuana product contains THC;
3745	3665		67. “Usable marijuana” means the dried leaves, flowers, oils,
3746	3666		vapors, waxes and other portions of the marijuana plant and any
3747	3667		mixture or preparation thereof, excluding seeds, roots , stems,
3748	3668		stalks and fan leaves; and
3749	3669		68. “Water-based medical marijuana concentra te” means a
3750	3670		concentrate that was produced by extracting cannabinoids from
3751	3671		medical marijuana through the use of only water, ice or dry ice.
3752	3672		SECTION 5. This act shall become effective November 1, 2022.
3753		-
3754		-	COMMITTEE REPORT BY: COMMITTEE ON ALCOHOL, TOBACCO AND CONTROLLED
3755		-	SUBSTANCES, dated 04/14/2022 - DO PASS, As Amended.
	3673	+	Passed the Senate the 23rd day of March, 2022.
	3674	+
	3675	+
	3676	+
	3677	+	Presiding Officer of the Senate
	3678	+
	3679	+
	3680	+	Passed the House of Representatives the ____ day of __________,
	3681	+	2022.
	3682	+
	3683	+
	3684	+
	3685	+	Presiding Officer of the House
	3686	+	of Representatives
	3687	+